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Executive summary
Introduction 
Background
An increasing number of cancer 
patients are living with the effects 
of their disease for signiicant 
lengths of time prior to reaching 
the end-of-life phase. The Active 
and Advanced Disease (AAD) 
working group was set up within 
the National Cancer Survivorship 
Initiative (NCSI) to consider issues 
of service design and delivery 
for people in this situation. They 
commissioned this rapid review of 
evidence to meet the following aim:
To review the literature on 
selected cancers in order to 
identify implications for the 
development of services to 
support patients experiencing 
dificulties associated with active 
and advanced disease.
Defining ‘active and  
advanced disease’
‘Active and advanced disease’ is not a 
term widely used in the literature, nor 
is it as yet clearly deined within NCSI 
documents. We therefore needed to 
create a working deinition to guide 
this review. To achieve this we drew 
on three sources of information:
•	 The small amount of literature 
which does use the AAD term with 
reference to cancer patients
•	 The wider literature on deinitions 
of survivorship
•	 An email consultation with 
16 health professionals and 
researchers with knowledge of 
cancer survivorship issues.
On the basis of this, we propose the 
following working deinition of ‘active 
and advanced disease’ in cancer:
‘Active and advanced disease’ 
(AAD) relates to physical, 
psychological and/or social 
problems experienced by people 
with cancer that is exhibiting 
local or wider (including 
metastatic) spread for solid 
tumours, or is signiicantly 
worsening for non-solid 
tumours. We exclude from the 
deinition problems speciically 
associated with diagnosis 
and the immediate effects of 
irst line treatment. We also 
exclude those issues that relate 
particularly to terminal care.
Search strategy
Given the potentially unmanageable 
scope of this review, we chose to 
focus on three types of cancer which 
have different trajectories, impacts 
on patients’ lives and support 
needs: bowel, prostate and multiple 
myeloma. Our main search term was 
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[cancer type] + SUPPORT; we then 
used a further 18 terms and applied 
nine exclusion criteria developed 
through an initial scoping search 
on bowel cancer. (See full report for 
details of search terms and exclusion 
criteria.) We used the following 
search engines: Medline, CINAHL, 
Web of Science and Cochrane. 
We also searched for grey literature 
with SIGLE, King’s Fund, Social 
Care online and NCAT. To ensure 
contemporary relevance and keep 
the literature search manageable we 
restricted it to items published since 
2003, in English. 
The search procedure involved the 
following steps:
1. Abstracts of all initial searches 
were reviewed by two members of 
the team.
 Those clearly not meeting the 
aims of the review were rejected.
2. Full papers were retrieved for 
those abstracts not rejected at 
stage one, and reviewed against 
exclusion criteria. Those to which 
one or more exclusion criteria 
applied were rejected.
3. In the course of reviewing the 
inal selection, additional targeted 
searches were carried out where 
we identiied areas of literature 
that had been overlooked.
Findings
For reasons of length we will not 
attempt to summarise the cancer-
speciic indings – please see the full 
report for the detail of these. Instead 
we will highlight the key issues that 
emerged in relation to each cancer 
type. The over-arching issues that we 
identiied across the three cancers are 
presented in our Discussion section.
Bowel cancer
Our initial search identiied 
312 abstracts; following further 
examination as outlined above 
we retained 58 items for review. 
Key issues emerging were:
•	 Co-morbidity and age 
•	 Chemotherapy in advanced 
disease Follow-up
•	 Information needs
•	 Partners’ and carers’ involvement 
in decision-making and support
•	 Assessment of patient needs and 
concerns
•	 Transport, inancial hardship and 
access to care.
Prostate cancer
We identiied 417 abstracts in our 
initial search, retaining 81 in the inal 
review. Key issues were:
•	 Patient quality of life
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•	 Patient experience:
 – Sexual problems, urinary 
incontinence and other  
physical symptoms
 – Psychological symptoms
 – Spirituality
•	 Information needs of patients  
and partners
•	 Impact on partners and  
wider family
•	 Psychosocial support and 
educational interventions
•	 Online and written informational 
and educational resources.
Multiple Myeloma
A total of 350 abstracts was identiied 
in the initial search. Following the 
further steps of our procedure we 
retained 111 items in the review. 
Key issues were:
•	 Fatigue and pain
•	 Information for patients: what to 
convey and how
•	 Supporting signiicant others
•	 Multidisciplinary working and 
the involvement of palliative care 
services 
•	 Treatment strategies to minimise 
inconvenience to patients and 
families 
•	 Availability of ‘best practice’ 
treatment
•	 Fear of recurrence.
Discussion
Examining both the similarities and 
the differences in the literatures 
relating to our three selected 
cancers, we identiied six main 
themes that need to be considered 
in the development of services for 
patients affected by AAD. These 
are summarised below, followed 
by suggested priorities for future 
research and development.
Recognising patient concerns
Professionals do not always recognise 
their patients’ priorities in care and 
support. This may be because they 
tend to look at patient experience 
through the lens of their own 
professional perspective and specialist 
interest. Also, there is good evidence 
that patients may play down some 
symptoms and concerns because they 
are resigned to them as ‘inevitable’ 
consequences of their illness, its 
treatment, and/or simply their age.
Patient and significant other 
information needs
The importance of clear, timely 
and properly targeted information 
for patients with cancer at all 
stages (and their signiicant others) 
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has long been acknowledged. 
Nevertheless, this was highlighted 
as a continuing area of concern for 
patients and families affected by AAD. 
We found evidence for the potential 
effectiveness of interventions to 
enhance the provision and utilisation 
of information in a range of settings 
and formats. Online information 
can be very useful, but given 
the age proile of many cancers 
(including those we looked at), 
other media remain important.
These include the use of telephone 
contacts, either for routine follow-up 
or as part of a targeted educational 
and support intervention, and printed 
material.
Involving and supporting 
significant others
Signiicant others (family members 
and/or friends) are a crucial 
source of support for patients with 
AAD; it is therefore important that 
they themselves are supported. 
We identiied more research – 
including more evaluations of 
interventions – targeted at the 
signiicant others of prostate cancer 
patients than bowel and multiple 
myeloma patients. Although the 
evidence regarding the effectiveness 
of such interventions is patchy, 
there was enough to suggest 
that involving signiicant others 
alongside patients – as in some 
prostate cancer support groups – 
can be helpful for both parties.
Issues of collaborative working
Effective communication and 
collaboration between different 
professionals is often essential to 
ensure the best possible care and 
support for patients with AAD (though 
often literature on this topic was 
aspirational rather than reporting on 
good practice). Not only the type of 
cancer but also the type of treatment 
patients were receiving could make 
a major difference to the range of 
services with which they were in 
contact. Hospital-based medical 
specialists are not necessarily the best 
clinicians to understand and meet the 
support needs of AAD patients; the 
potential of nurses (especially clinical 
nurse specialists and advanced nurse 
practitioners) to address their needs 
was frequently highlighted. However, 
there was a lack of reference in this 
literature to the actual or potential 
role of community nurses – or even 
GPs – in supporting AAD patients.
Costs of advanced disease and 
support interventions
Within our chosen cancers we 
found minimal evidence concerning 
the costs of AAD, either directly 
to patients and families or to the 
wider economy. What little we found 
tended to be focused on personal 
costs – for instance, how transport 
issues impacted on uptake of 
services. The wider literature on the 
costs of cancer tends not to specify 
stage of disease and either looks 
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at cancer as a whole, or includes 
a selection of speciic cancers by 
convenience with little or no site-
speciic analysis. It is reasonable 
to extrapolate from some of this 
general literature that some of the 
costs may be higher for patients living 
with active, advanced disease than 
those with earlier stage disease or in 
long-term remission. For example, 
AAD patients may be receiving 
ongoing treatment, may be unable 
to work or have to take signiicant 
time off from work, and may have 
multiple service involvement.
Neglect of minority perspectives
In all our cancers, authors expressed 
concerns about the lack of research 
and/or interventions aimed at the 
support needs of minority groups 
– especially ethnic minorities but 
also gay men in relation to prostate 
cancer. (Sexuality is not considered in 
the bowel and myeloma literatures 
relating to AAD at all as far as we 
could see).
 
Future research and 
development priorities
On the basis of this review we would 
suggest the following priority issues 
for further research and related 
service development:
1. There is a need to develop and 
evaluate methods for improving 
staff awareness of how patients 
and signiicant others are 
affected by AAD. Multidisciplinary 
initiatives may be of value, as a 
way to counter the tendency for 
clinical staff (and researchers) to 
look at patient concerns through 
their ‘specialist lens’.
2.   Further development is needed of 
measures and assessment tools 
sensitive to quality of life issues for 
patients with active and advanced 
disease.
3.   We need to develop a better 
understanding of how different 
segments of the population of 
patients affected by AAD and their 
signiicant others understand and 
make use of information relevant 
to their circumstances.
 This would include looking at such 
factors as age, gender, ethnicity 
and education level in relation to 
different communication media 
and contexts, and the impact 
of this on access to services. 
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The timeliness of information 
to address the concerns of AAD 
patients at different points of the 
disease trajectory should also be 
an important focus.
4.  Support interventions including 
signiicant others need to be 
developed and evaluated across 
all cancer types for those affected 
by AAD. Services generally should 
consider how they can better 
engage with patients’ key social 
support networks. Some of the 
interventions we have identiied 
for prostate cancer patients 
and their partners may provide 
a useful model, though the 
circumstances relating to speciic 
cancer types need to be borne 
in mind. Also, interventions 
and service developments need 
to consider wider family and 
friendship networks, and the 
speciic needs of people from 
ethnic and sexual minorities.
5.   Collaborative working between 
professions, services and sectors 
is crucial to the support of people 
affected by AAD. New staff roles 
– or changes to existing roles – 
could play a part in facilitating 
this. Developments such as the 
Macmillan One-to-One projects, 
nurse-led telephone follow-up, 
and the roll-out of the Midhurst 
approach to community palliative 
care may serve as exemplars, 
though it will be important to 
ensure that speciic issues relating 
to AAD are addressed.
6.   Research into the costs of cancer 
(personal, NHS and for the 
wider economy) needs to include 
more focused attention on the 
experiences of those affected by 
AAD and its treatment.
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1.1 Background: the NCSI 
AAD group
The National Cancer Survivorship 
Initiative (NCSI, 2010) was set up 
in response to the NHS Cancer 
Reform Strategy (Department of 
Health, 2007) as a collaboration 
between Macmillan Cancer Support, 
the Department of Health and 
NHS Improvement, with the goal 
to achieve a better understanding 
of the experiences of cancer 
survivors and to advocate for the 
provision of services to support 
them. Within this broad remit, it 
was recognised that there was a 
particular group of patients whose 
needs were commonly neglected; 
people who were experiencing the 
ongoing effects of cancer beyond 
irst-line treatment but who were 
not at end of life. The Active and 
Advanced Disease (AAD) working 
group was created to consider 
issues of relevance to such people.
1.2 Aims of this review
This project set out to meet the 
following aim:
To review the literature on 
selected cancers in order to 
identify implications for the 
development of services to 
support patients experiencing 
dificulties associated with active 
and advanced disease.
1. Introduction
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‘Active and advanced disease’ is 
not a term that has been widely 
and routinely used in the literature 
up to now. In order to carry out 
an evidence search we therefore 
needed to formulate a working 
deinition. To assist us in doing this 
we undertook two exercises. First, we 
carried out a search of the literature 
for material discussing issues of 
deinition in relation to ‘active and 
advanced disease’ and terms that 
might overlap with it. Second, we 
informally consulted professionals 
and researchers with an interest in 
this area as to their understanding of 
the term and thoughts about its utility.
2.1 Definitions of active  
and advanced disease in  
the literature
We performed a Google Scholar1 
search to identify any papers 
using the exact phrase ‘active 
and advanced disease‘ or ‘active 
advanced disease‘ and also including 
the term ‘cancer‘. Our search 
produced 36 items. By way of 
comparison, the exact term ‘cancer 
survivorship‘ produced 10,500 items, 
with 642 in the current year (2013) 
up to April. Looking further at the 
AAD items, 12 referred to non-cancer 
conditions (including liver diseases, 
lupus, HIV and endometriosis) leaving 
a total of 24 items using the term 
AAD in relation to cancer. Amongst 
these items, most related to a single 
cancer or group of cancers; only ive 
were about cancer in general. In the 
remaining 19, what was immediately 
striking was the high number relating 
to cancers of the blood or lymphatic 
system – 12 articles were in this 
category (Hodgkins lymphoma = 4, 
Non-Hodgkins lymphoma = 1, 
leukemias = 5, multiple myeloma 
= 2), compared to 7 for all others.
We obtained full text copies of all 
the articles retrieved in the above 
search and looked at exactly how 
and in what context the term ‘active 
(and) advanced disease‘ was used. 
It was immediately evident that not 
one of the publications we found 
gave a full, conceptual deinition of 
this term. Although not presenting 
a formal deinition, the report 
commissioned by the NCSI on 
‘Determining Research Priorities for 
Cancer Survivorship‘ (Richardson 
et al, 2011; including technical 
appendices 2: Ziegler et al and 3: 
Armes et al) goes further than any 
other source to locate an ‘active and 
advanced disease‘ stage in the cancer 
survivorship journey. It depicts AAD 
as beyond the post-treatment phase, 
remission and initial recurrence, 
but not incorporating end-of-life. 
The low-chart used to depict stages 
of survivorship recognises that 
progression between them is not 
2. Deining ‘active and  
advanced disease’
RapidReview_Br0924_4.indd   12 13/02/2014   16:46
Supporting people with active and advanced disease: a rapid review of the evidence  13 
purely linear – some patients may 
enter an ‘active and advanced‘ phase 
straight from diagnosis, rather than 
after remission and recurrence.
Amongst the rest of the articles 
retrieved, two gave highly technical 
operational deinitions where they 
had carried out comparisons between 
an active and advanced group and 
an early stage group in stem cell 
treatment for acute myeloid leukemia 
and associated conditions (Bertz et al, 
2012; Krauter et al, 2011). In other 
articles the term was most commonly 
used to refer to patients with 
refractory illness (eg Merl, Hoimes, 
Pham, & Saif, 2009), or as a contrast 
to patients whose illness was ‘disease 
free‘/‘inactive‘ (eg Whiteside, 2006; 
Henderson et al, 1974) or early stage 
(Gladue, Brown, & Zwillich, 2010). 
One article located AAD (at least by 
implication) at the latter end of the 
survivorship spectrum (Cella, 1987); 
another made reference to the NCSI 
AAD workstream in locating AAD in 
a ‘long-term phase‘, distinguishing 
it from a long-term ‘disease free‘ 
state (Jefford et al, 2013). In one 
article addressing, ‘the aftermath of 
lung cancer‘, the term AAD is used 
to refer to patients who do not go on 
to survive long-term (Maliski, Sarna, 
Evangelista, & Padilla, 2003).
2.2 Consultation with 
professionals and researchers
To supplement our search of the 
literature for usage of the term 
‘active and advanced disease‘ we 
carried out an informal consultation 
of personal contacts with expertise 
and experience in the areas of 
survivorship and palliative care. 
We asked them to describe what the 
term ‘active and advanced disease‘ 
meant to them, and how (if at all) 
they used it. In a few cases we asked 
some further more speciic questions 
to clarify their positions. Overall 
we had responses from 16 people 
(everyone we contacted); these 
included three nurses, seven doctors, 
four pharmacists and two others (one 
palliative care researcher without a 
health professional background and 
one health service manager). Exactly 
half of the respondents (eight) were 
working only as practitioners; the 
other half had academic posts with 
varying levels of current or recent 
clinical involvement. Five of the 
respondents were members of the 
MacPaCC group (Macmillan Palliative 
Care research collaborative). After we 
had received the email responses NK 
discussed some of the general issues 
arising at a meeting of MacPaCC in 
March 2013.
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It was immediately apparent that 
‘active and advanced disease‘ was 
not a term commonly used by our 
respondents. Some explicitly stated 
that they did not use it (‘It’s not a 
phrase we use and isn’t at all easy 
to answer‘: Specialist Palliative 
Care Pharmacist). Ten of the sixteen 
deined ‘active‘ and ‘advanced‘ 
as quite separate things: some 
constructed a deinition of the 
combined term by working out where 
the two overlapped, while others did 
not provide any such deinition.
‘My “gut feeling” would be that 
“active and advanced disease” 
(it seems to be a single term) 
that the cancer, previously 
diagnosed, was (a) still present, 
and therefore not “cured”,  
and (b) had spread from 
the original site, either by 
metastases (ie distant spread) or 
by local spread.’
(Academic GP)
‘Active disease and advanced 
disease are two different things 
to me. Active disease means 
that the cancer (in this case) 
is growing or worsening (for 
non-solid tumors), cells are 
differentiating and dividing 
abnormally. Advanced disease 
may or may not be active but 
it is a late stage of the disease 
where there has been spread 
not only referring to distant 
metastasis but also to local/
regional spread that is causing 
problems in other systems of  
the body.’
(Nurse, Clinical Researcher)
For those respondents who did 
attempt to deine the term there 
was strong agreement that AAD 
includes patients whose disease 
had spread either locally or through 
metasteses (or both). There were 
differing views, though, on whether 
it should exclude those where 
cure remained a possibility and 
similarly as to whether the term 
should encompass those who are 
‘actively dying‘. Three respondents 
excluded patients in remission 
from the deinition of AAD.
RapidReview_Br0924_4.indd   14 13/02/2014   16:46
Supporting people with active and advanced disease: a rapid review of the evidence  15 
‘I think it means disease that is 
not currently in remission, and 
is in the advanced stages – ie 
probably only suitable for a 
palliative approach to care, 
unlikely to be curable.’
(Nurse, clinical researcher recently  
in practice)
‘“Active and advanced disease” 
in a cancer patient to me  
means they could still be 
receiving potentially curative 
treatments with a view to 
achieving remission.’
(Macmillan Specialist Palliative  
Care Pharmacist)
One respondent – a consultant 
oncologist – began her response by 
emphasising that concepts such as 
AAD were likely to vary in meaning 
for different cancer sites, because of 
differing trajectories. Three referred 
to AAD in relation to long-term 
conditions (LTCs) other than cancer; 
one (a community pharmacist) 
mentioned ‘some cancers‘ alongside 
a range of chronic and deteriorating 
LTCs for which she might apply the 
term AAD. In contrast, our community 
matron respondent suggested a 
rather different interpretation of AAD 
with regard to LTCs and cancers. 
While she took ‘active‘ to mean 
‘causing symptoms‘ for both types of 
condition, she saw ‘advanced‘ cancer 
as referring to ‘…entering the last 
stages of the disease you know the 
end won’t be long‘. In contrast she 
saw ‘advanced‘ LTCs as ‘could be 
weeks/months or 2–3 years.‘
In the discussion at the MacPaCC 
meeting, NK summarised the main 
points emerging from the email 
responses. (Note that ive of those 
we consulted by email were also 
present at the meeting). Colleagues 
reinforced the view that deining AAD 
is problematic. Nevertheless, they 
recognised that there are patients 
who are living with and signiicantly 
affected by cancer but not at end of 
life, for whom appropriate support 
may not exist or may be dificult to 
access. A strong concern arising 
from the discussion was that any 
deinition of AAD should not be used 
to determine eligibility for services. 
Access should be based on individual 
patient need rather than whether a 
person its a category such as AAD.
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2.3 Survivorship and AAD
Dificulties in deining AAD relect 
wider challenges in terminology 
relating to the illness trajectories 
experienced by cancer patients. 
Even well-established terms such as 
‘palliative’, ‘supportive’ and ‘end-
of-life’ are recognised as potentially 
problematic (Hui et al, 2013). 
However, debates about the notion 
of ‘survivorship’ are of most direct 
relevance to the focus of this review. 
The concept of cancer survivorship 
originates in America, and is usually 
attributed to the work of Mullan 
(1985). Having had personal as well 
as professional medical experience 
of cancer he was concerned that the 
needs of those living past a cancer 
diagnosis were neglected. Mullan 
(1985) used the term ‘cancer survivor’ 
to apply to all cancer patients from 
diagnosis to end-of-life, and many 
within the survivorship movement 
continue to do so. For example, 
the National Coalition for Cancer 
Survivors in the US says a cancer 
survivor is ‘anyone living with a 
history of cancer – from the moment 
of diagnosis through the remainder 
of life’ (Astrow, 2012). The NCSI 
also uses a broad deinition, from 
primary treatment through to active 
and advanced disease (NCSI, 2010). 
In contrast, many of those involved 
in policy and practice development 
deine survivorship as a distinct stage 
in the cancer ‘journey’. In the US, the 
Committee on Cancer Survivorship 
of the National Cancer Board 
(Hewitt, Greenield & Stovall, 2005) 
deined survivorship as the phase of 
care following primary treatment. 
Empirical research commonly 
operationalises survivorship in terms 
of either the end of ‘active treatment’ 
or a number of years post-treatment, 
though both these approaches are 
fraught with dificulty (see Khan, 
Rose & Evans, 2012a, for a useful 
discussion of these issues).
Despite the widespread use of the 
concept of survivorship and of the 
term ‘cancer survivor’ there remain 
strongly differing opinions about it 
amongst clinicians, academics and 
patients. Those who support the 
notion of cancer survivorship see it as 
empowering for patients (Deimling, 
Bowman, & Wagner, 2007) and 
believe that it helps focus attention 
on the provision of services beyond 
the historical emphasis on diagnosis 
and treatment on one hand and 
end-of-life on the other (Hoffman & 
Stovall, 2006; Richards, Corner & 
Maher, 2011). Those critical point 
out that as a very broad term it 
may conceal important differences 
amongst those to whom the label is 
attached (Bell & Ristovski-Skijepcevic, 
2013). Many patients do not feel 
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comfortable with the term (Khan, 
Harrison, Rose, Ward, & Evans, 
2012b) perhaps more so in the 
UK than the US – and its use may 
serve to reinforce a ‘cancer patient’ 
identity rather than help people 
move on from successful treatment 
(Astrow, 2012; Khan, et al, 2012b). 
Khan et al (2012a) argue that for 
some people the term ‘survivor’ may 
actually increase fears by giving the 
impression that cancer mortality 
rates are higher than they are.
The debates about the concept 
of cancer survivorship are highly 
relevant to the question of how 
we deine ‘active and advanced 
disease’. The term is used by the 
NCSI to refer to a particular subset 
of ‘survivorship’ and with much 
the same aims as those who have 
promoted the wider term; to draw 
attention to needs, ensure this 
category of people affected by cancer 
is considered in policy and practice 
developments, and enhance the 
availability of support. However, the 
use of the term AAD to apply to a 
particular group of people has some 
of the same potential pitfalls as we 
have noted regarding ‘survivorship’; 
it may be so broad as to obscure 
crucial differences in the needs and 
concerns amongst the people to 
whom it is applied, and it may not 
be understood or seen as helpful by 
cancer patients themselves. As one of 
our email respondents said:
I will say that the terms are 
jargon and whatever clinicians 
and researchers call it we 
should check that patients and 
families know/understand what 
we mean by them. 
(Nurse, Clinical Researcher)
In the discussion of the concept of 
AAD at MacPaCC, many members 
were concerned that it could end up 
being used in a ‘tick-box’ fashion, 
to allow – or deny – patients access 
to particular services. There was a 
strong feeling that services should 
be responsive to individual needs 
and not ‘rationed’ to those who meet 
criteria that are inevitably to some 
extent arbitrary.
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2.4 A working definition of 
Active and Advanced Disease
While recognising that deining what 
constitutes active and advanced 
disease is problematic, we needed 
at least a working deinition to guide 
our literature search. We hoped that 
our examination of the indings from 
this search would itself throw light 
upon the issue of deinition. With a 
view to the issues discussed above, 
we did not feel it would be realistic 
to try to deine a distinct stage of 
survivorship that could be called 
‘active and advanced disease’ for 
any and all cancers. Rather, we took 
the view that the term highlights a 
range of problems which people may 
experience when their cancer has 
certain features. We therefore used 
the following working deinition to 
guide our search:
‘Active and advanced disease’ 
(AAD) relates to physical, 
psychological and/or social 
problems experienced by people 
with cancer that is exhibiting 
local or wider (including 
metastatic) spread for solid 
tumours, or is signiicantly 
worsening for non-solid 
tumours. We exclude from the 
deinition problems speciically 
associated with diagnosis 
and the immediate effects of 
irst line treatment. We also 
exclude those issues that relate 
particularly to terminal care.
This deinition overlaps with that 
recently suggested for ‘chronic 
cancer’ (Harley, Pini, Bartlett & 
Velikova, 2012) but is not identical. 
Here, ‘active and advanced 
disease’ is a broader concept as, 
unlike chronic cancer it includes 
those for whom active anti-
cancer treatments that can slow 
progression are not available.
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In this section we will explain how we 
went about searching the literature 
in order to meet the aims of the 
review. We will cover our choices 
of: particular cancers upon which to 
focus; search terms and exclusion 
criteria; search engines. We will 
conclude by describing how we 
managed the search procedure and 
went about identifying key papers 
within our overall search results.
3.1 Selecting cancers for  
the search
It was clear from an initial overview 
of the literature and from the work 
described above on deining AAD 
that there are important differences 
between types of cancer as to what 
counts as AAD and the support 
needs associated with it. In addition, 
given that AAD refers to a broad, 
heterogenous group of patients 
that cannot easily be distinguished 
from other categories, it was well 
beyond the scope and resources 
of this rapid review to attempt to 
examine literature relating to any 
and all cancers. In consultation 
with the project commissioners at 
Macmillan, we therefore decided to 
focus on three cancers with different 
trajectories, impacts on patients’ lives 
and likely support needs. Our chosen 
cancers are: bowel cancer, prostate 
cancer and multiple myeloma. In 
our searches we included research 
relating to any one or more of our 
chosen cancers either on their own or 
alongside other cancers.
3.2 Search terms and 
exclusion criteria
Throughout our search of the 
literature, our main search term was 
SUPPORT paired with the names of 
each of the three chosen cancers 
in turn. We then added a series of 
other search terms that would help 
to ensure we focused on issues 
relevant to the support of people 
living with AAD. We also identiied 
exclusion criteria to help us reject 
abstracts that were retrieved through 
our searches but did not help us 
to meet our aims. (Note that we 
included literature relevant to the 
support needs of carers/signiicant 
others.) In order to keep the search 
manageable and to ensure evidence 
was of contemporary relevance we 
restricted our search to material 
published no earlier than 2003.
We trialed our search terms and 
exclusion criteria through an initial 
search on bowel cancer, and 
made some adjustments to them 
as a result. The inal list is shown 
in table 1, on the next page:
3. Search strategy
RapidReview_Br0924_4.indd   19 13/02/2014   16:46
20  Supporting people with active and advanced disease: a rapid review of the evidence
Table 1: Search terms and exclusion criteria
Search term Exclusion criteria
[cancer type] + support + Does not relate (at least in part) to 
people with active and advanced 
disease
•	 Intervention
•	 Symptoms
•	 Co-morbidity 
•	 Treatment effects Family
•	 Carers
•	 Costs/beneits
•	 Survivorship
•	 Basic biomedical research
•	 Animal-based research
•	 Where the only or main focus is 
on screening
•	 Where the only or main focus is 
on diagnosis (including clinical 
and/or psycho-social issues of 
diagnosis)
•	 Secondary 
•	 Psycho-social 
•	 Recurrence 
•	 Progression 
•	 Services 
•	 Palliative
•	 Side effects
•	 Peer support
•	 Social networking
•	 Patient information sharing
•	 Focus on irst-line treatment and 
its immediate effects
•	 Focus on terminal phase 
(treatment and/or management  
of inal days/hours of life) 
•	 Prevention/public health
•	 Non-UK settings where the issues 
discussed are not relevant to UK 
health service or societal contexts
•	 Narrowly focused on 
methodological developments
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3.3 Search engines
We used the following search engines 
for our searches in relation to each 
cancer:
Medline, CINAHL, Web of Science 
and Cochrane (systematic reviews, 
trials and register).
3.4 Search procedure
For each of the chosen cancers we 
searched using [NAME OF CANCER] 
+ SUPPORT plus each of the other 
search terms. Where initial results 
suggested a more focused search 
might be helpful we further reined. 
Abstracts of all initial search results 
were then retrieved and reviewed 
by two members of the team, 
applying the exclusion criteria and 
categorised as definite inclusion for 
review, possible inclusion for review, 
and rejection. Full papers were then 
retrieved for the deinite and possible 
inclusion categories, and checked 
again against the exclusion criteria. 
A inal selection was then made 
and these papers reviewed. As we 
began to identify key issues from 
the articles we were reading, from 
time to time additional material was 
uncovered that could contribute to 
our understanding – for instance 
through following up citations. 
We also periodically checked for 
relevant material published while 
we were carrying out the search. 
One outcome of this process was 
the identiication for each cancer 
of a relatively small number of key 
papers that were especially relevant 
to the aims of this rapid review. 
These included empirical studies, 
reviews and theoretical articles. 
They may be seen as constituting a 
‘recommended reading’ list for those 
interested in active and advanced 
disease in relation to the chosen 
cancers; summary details of these are 
provided in the appendix.
Searching grey literature
The AAD group directed us to 
relevant grey literature, particularly 
publications from the National 
Cancer Survivor Initiative (NCSI). 
We also searched relevant cancer 
charities for each individual cancer 
plus the following sources;
•	 SIGLE
•	 Kings Fund
•	 Social Care online
•	 NCAT
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In this section we will present the 
indings from our review for each 
of the three cancer types in turn. 
We will provide an overview of the 
outcomes of the search process 
related to each cancer, before moving 
on to highlight key issues emerging 
from the publications we reviewed. 
In identifying key issues we focused 
on the aims of this review as a whole 
and therefore looked particularly at 
areas where the literature had clear 
implications for policy and practice 
related to the support of people 
living with AAD. In a few cases, we 
have drawn attention to areas where 
there are substantial and signiicant 
gaps in the literature that warrant 
future research to ensure people with 
AAD can be properly supported.
4A. Bowel cancer
Bowel or Colorectal Cancer (CRC) is 
the fourth most commonly diagnosed 
cancer in the UK and the second most 
common cause of cancer death. In 
2010 there were 40,695 new cases, 
22,834 (56%) in men and 17,861 
(44%) in women. Almost two thirds 
of cancers occur in the colon and just 
over a third in the rectum including 
the anus (Cancer Research UK 
[CRUK], 2013). Patients presenting 
with advanced disease at diagnosis 
are more likely to have colon cancer. 
In the recent National Bowel Cancer 
Audit (National Bowel Cancer Audit 
[NBCA], 2012) nearly a third of those 
with colon cancer were found to have 
stage T4 disease when undergoing 
major surgery and a higher 
proportion of people with a primary 
tumour in the colon underwent 
initial surgery as an emergency. As a 
consequence postoperative mortality 
rates were high in those with colon 
cancer, overall around 5.1% of cases 
(NBCA, 2012). The audit recognised 
much effort had been directed at 
improving outcomes by changing 
clinical practice yet a number of 
challenges remained, not least the 
complexities of care management 
particularly in a cancer that 
disproportionally affects older people.
4. Findings
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We undertook an initial search 
based on the terms and exclusion 
criteria described above, which 
yielded 312 abstracts. Review of 
the abstracts resulted in 58 articles 
being retained. Most abstracts and 
articles retrieved in related to CRC 
populations treated with ‘curative 
intent’, or recruited people with 
different cancers including colorectal. 
Much of the research, particularly 
that related to psychosocial needs 
of people with bowel cancer beyond 
initial treatment, excluded those with 
active and advanced disease. As a 
proportion of individuals will go on 
to develop metastatic disease2 some 
articles were included where the 
focus of the research was not limited 
to those likely to survive disease free 
beyond ive years, and/or included 
participants where the stage of 
disease was unclear. The terms 
‘active’ or ‘advanced’ disease across 
the bowel literature were infrequently 
and inconsistently applied; this is 
similar to the ambiguity surrounding 
the terms ‘palliative’ and ‘survivor’ 
(NBCA 2012, van Mechelen et 
al, 2012) and sometimes used 
interchangeably. No study used the 
combined term ‘active and advanced’ 
although some used advanced 
disease alone. Those studies where 
the term advanced disease was 
used consistently tended to refer to 
a sub-population of CRC survivors 
including: those living with (active) 
cancer from diagnosis, or recurrence 
of disease following treatment with 
curative intent (Phillips & Currow, 
2010), or with local (unresectable) 
disease or with metastatic disease 
(Simmonds, 2000) that may not 
be curable (Leighl et al, 2011).
The irst scoping of active and 
advanced disease in bowel cancer 
identiied a number of issues. These 
were used as the basis for a series of 
targeted searches related to speciic 
topics and a further 76 articles 
were identiied, relating to: to co-
morbidity and age, chemotherapy 
in advanced disease, follow-up, 
information needs, partners’/carers’ 
involvement in decision-making and 
support, patient adjustment and 
concerns beyond initial treatment, 
and transport, inancial hardship 
and access to care. Table 2 (in 
appendices) contains ‘key articles’ 
retained from the initial scoping 
review that remained salient 
after further consideration and 
signiicant articles identiied from 
the subsequent targeted reviews.
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4A.1 Co-morbidity and age
Bowel cancer affects the older 
population disproportionately 
(Dunn et al, 2006; CRUK, 2013) and 
approximately three quarters of new 
cases occur in those aged 65 or over 
(NICE 2011). In the period 2008–
2010 (NBCA 2012) the majority of 
new cases of CRC were diagnosed 
in people over 65 years of age 
(73%), and over 40% in those over 
75 years. In general older people 
are more likely to experience bowel 
cancer alongside existing health 
problems (Bellury et al, 2011; Movsas 
& Extermann, 2012). Age and co-
morbidity combined can bring added 
complexity and burden to treatment, 
reducing quality of life (Bellury et al, 
2011; Dunn et al, 2006; Fu, Zhao, 
Gao, Barber & Liu, 2011; Hornbrook 
et al, 2011; Steginga, Lynch, 
Hawkes, Dunn, & Aitken, 2009), 
increased levels of postoperative 
mortality and lower overall ive year 
survival – the latter not necessarily 
attributable to cancer (Pedrazzani 
et al, 2009). Older cancer survivors 
(≥ 70 years or over) are more 
likely to report poorer self-rated 
health and make more frequent 
visits to the doctor compared with 
people without cancer of a similar 
age (Grov, Fossa & Dahl, 2011). 
This may be a relection of feeling 
vulnerable as a consequence of 
having cancer (Shaha & Cox, 2003), 
and having heightened awareness 
of bodily cues. They may also be 
less reticent to present symptoms 
to a health provider than non-
cancer populations of a similar age. 
The complexity of how comorbidity 
affects patients with CRC and the 
way they use services is under-
researched (Bellury et al, 2011).
Current NICE Guidance states 
‘treatment and care should take 
into account patients’ needs and 
preferences’ (2011: 5). Yet Beaver et 
al (2007) found patient willingness 
to engage in decision-making 
was perceived as age related by 
some clinicians. Whilst some older 
patients may well adopt a passive 
role in consultations there was 
evidence that the way in which 
choices were presented by clinicians 
often confused rather than enabled 
(Keating et al, 2010; Sarfati et al, 
2009; Simpson & Whyte, 2006). 
Confusion could be compounded by 
levels of health literacy or socialised 
behaviours, all contributing to a 
perception of unwillingness to be 
involved (Paasche-Orlow, Parker, 
Gazmararian, Nielsen-Bohlman 
& Rudd, 2004) and ‘doctor knows 
best’. In Beaver et al‘s (2007) 
qualitative interview study, with a 
purposive sample of clinicians (n=35) 
drawn from a range of disciplines 
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representing the multidisciplinary 
cancer team, choice ‘was frequently 
qualiied to describe a process of 
leading, negotiating, suggesting 
and explaining’ (p.729). They 
also found those patients who 
actively enquired were more likely 
to be presented with choices.
In general co-morbidities are 
associated with poorer outcomes 
but not all non-cancer conditions 
and their treatments appear to have 
similar effects. Some conditions 
such as previous malignancy, 
chronic obstructive pulmonary 
disease (COPD) or cardiovascular 
disease (CVD) in colon cancer, and 
COPD, hypertension, and diabetes 
accompanied by hypertension in 
rectal cancer may inluence treatment 
and survival due to the underlying 
pathology, treatment interactions or 
debilitative effects of the co-existing 
illness (Lemmens et al, 2005). 
Existence of co-morbidities may 
also guide treatment choice and/
or inluence clinicians to use non-
standard treatments to reduce toxicity 
effects on patients already burdened 
with other conditions (Samarasinghe 
& Wiles, 2012; Hornbrook et al, 
2011). The complexities of case 
management when overlaid with 
non-cancer illness, or complications 
associated with late presentation 
with extensive disease requiring 
emergency intervention, are 
more likely to impact on cancer 
outcomes (NBCA, 2012). There is 
also some evidence that co-
morbidity and socioeconomic 
deprivation may have some impact 
on survival and non-cancer death 
(Shankaran, Jolly, Blough & Ramsey, 
2012; Wrigley et al, 2003).
Patients may experience some 
anxieties about interactions between 
cancer treatment and treatments for 
pre-existing conditions. They may 
also be concerned about cancer 
treatment exacerbating pre-existing 
conditions (Simpson & Whyte, 
2006). Since much care of long 
term illness is now managed in 
primary care this interplay between 
existing conditions and CRC may 
result in complex presentation in 
primary care. Little evidence was 
found that identiied the role of GPs 
(Hanks, Veitch & Harris, 2008) or 
other primary care clinicians such 
as community matrons involved in 
complex chronic case management 
(McHugh, Horne, Chalmers & 
Luker, 2009). Ipsos MORi (2012), 
identiied that 38% of cancer patients 
had contacted their GP with cancer 
related concerns in the previous 
six months; what is unknown is the 
number of primary care contacts for 
non-cancer related concerns and the 
inter-relationships between the two.
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People experience bodily cues or 
sensations that may or may not 
indicate illness as part of daily life 
(Miaskowski, Dodd, & Lee, 2004; 
Miaskowski, Aouizerat, Dodd & 
Cooper, 2007). Interpretation and 
day-to-day management of symptoms 
often falls to the patient, family and 
carers. Symptoms, irrespective of 
cause, when unrelieved can have a 
negative impact on quality of life, 
functioning and mood particularly 
in advanced disease (Dodd, Cho, 
Cooper, & Miaskowski,2010; 
Smith et al, 2006; Miaskowski et 
al, 2004, 2007; Walsh & Rybicki, 
2006). Recognising symptoms that 
occur together, in clusters and over 
time, may improve assessment, 
speedier management and bring 
therapeutic beneit to patients (Fan, 
Filipczak & Chow, 2007; Walsh and 
Rybicki, 2006; Taylor, Richardson 
& Cowley, 2011) particular those 
experienced by people with AAD.
Certain clinical signs such as bowel 
obstruction, perforation and change 
in bowel habits are hypothesised 
to indicate poorer prognosis at 
initial presentation; likewise bowel 
obstruction and change in bowel 
habits is seen more frequently in 
those with ‘early’ recurrence in bowel 
cancer (Kanwar, Poolla & Majumdar, 
2012). Much of the symptom cluster 
research is at an early stage and has 
been undertaken with heterogeneous 
groups of cancer patients (including 
some bowel cancer), breast (Dodd 
et al, 2010), lung cancer, or people 
receiving adjuvant chemotherapy 
(Skerman, Yates & Battistutta, 2012). 
Symptom cluster research offers 
a range of potential beneits for 
understanding and intervening to 
support CRC patients with AAD 
(Brant et al, 2011; Fan et al, 2007; 
Miakowski et al, 2004, 2007; 
Skerman, 2010; Skerman et al, 
2012; Walsh and Rybicki, 2006).
4A.2 Chemotherapy in  
advanced disease
Chemotherapy treatment for 
advanced colorectal cancer3 is aimed 
at prolonging survival, controlling 
symptoms and maintaining or 
improving quality of life. Over a 
decade ago a review concluded 
that signiicant improvements in 
survival (25%) were gained from 
chemotherapy for advanced CRC 
(Best et al, 2000). The same review 
concluded that chemotherapy was 
effective across age bands with 
some caveats. People aged 75 years 
and older were poorly represented 
in clinical trials, so there was 
limited data to conirm, or refute, 
effectiveness of chemotherapy in 
this group, alongside poor reporting 
of dose reduction used to minimise 
treatment toxicity (Simmonds, 2000; 
Grov, et al, 2011). Age may also 
be an inluencing factor in terms of 
RapidReview_Br0924_4.indd   26 13/02/2014   16:46
Supporting people with active and advanced disease: a rapid review of the evidence  27 
access to chemotherapy for AAD 
in patients with CRC (Lemmens et 
al, 2005; Keating et al, 2008), and 
may inluence how clinicians present 
treatment choices particularly in 
relation to adjuvant or palliative 
chemotherapy, and invitations 
to participate in trials (Beaver et 
al, 2007; Leighl et al, 2011).
A number of different delivery and 
support models were identiied for 
individuals undergoing chemotherapy 
for advanced cancer. One Italian 
study involved a psychological 
assessment undertaken by a clinical 
psychologist with ongoing monitoring 
over the course of treatment with 
positive results (Pugliese et al, 2006). 
Most of the UK studies tested different 
nurse-led models of supportive care 
associated with the administration 
of oral capecitabine, driven by 
the advantages this therapy offers 
in terms of convenience and cost 
effectiveness (Oakley et al, 2010). 
There is, nevertheless, recognition 
that toxicity can be a problem despite 
survival beneits (Craven, Hughes, 
Burton, Saunders & Molassiotis, 
2013) and concerns have been raised 
about safe practice, monitoring and 
availability of nurse-led support for 
oral chemotherapy in general (Oakley 
et al, 2010). An audit of a nurse- 
and pharmacist-led home-based 
chemotherapy service for patients 
receiving irst line treatment with oral 
capecitabine (MacLeod et al, 2007), 
found high patient satisfaction and 
level of support reassuring. Similarly 
a trial comparing home care support 
versus normal care found symptom 
management was better and use of 
unplanned services lower in those 
receiving home care (Molassiotis et al, 
2009). A follow on audit by the same 
team comparing outcomes from 
standard care, nurse-led home care 
and nurse-led telephone support for 
patients receiving oral capecitabine 
found telephone follow up was 
as effective as standard care for 
management of some toxicities (chest 
pain, vomiting, nausea, insomnia) 
and similar impact to home care with 
other symptoms such as diarrhoea 
and insomnia, (Craven et al, 2013). 
The audit authors recommended a 
full RCT with economic assessment 
to assess cost-effectiveness of 
different support models.
The interplay between co-morbidities, 
co-incidence of symptoms and time 
over a course of chemotherapy 
is largely unmapped (Brant et al, 
2011; Ekholm, Grönberg, Börjeson, 
& Berterö, 2013; Skerman 2010; 
Skerman et al, 2012). Brant et 
al (2011) modelled incidence 
of common symptoms such as 
depression, distress, fatigue, pain 
and sleep disturbance over the 
timeline of chemotherapy, with a 
heterogeneous sample of cancer 
patients. They found co-morbidities 
were a signiicant predictor of fatigue 
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at baseline and sleep disturbance 
over the course of treatment (Brant 
et al, 2011). Greater levels of pain 
were associated with those receiving 
both chemotherapy and radiotherapy. 
Early work examining symptom 
clustering and chemotherapy has 
begun to identify clusters that appear 
stable over time independent of 
treatment and primary tumour 
site (Skerman et al, 2012).
4A.3 Follow-up
Approximately 50% of people with 
colorectal cancer survive beyond 
ive years disease free and some 
will experience distressing physical, 
functional and, or psychological 
consequences of the disease and 
its treatment (Appleton, Goodlad, 
Irvine, Poole & Wall, 2013; Baravelli 
et al, 2009; Samarasinghe & Wiles, 
2012; Taylor & Morgan, 2011). 
A challenge for health providers is 
providing adequate follow up4 that 
meets the support needs of disease-
free survivors with complex needs, 
whilst ensuring optimum surveillance 
for those at greater risk of recurrence 
or developing secondary disease, 
or requiring management of AAD. 
Numerous approaches for integrating 
surveillance, detection and support 
to optimise quality of life have been 
investigated (Samarasinghe & Wiles, 
2012; Baravelli et al, 2009; Cusack 
& Taylor, 2010). Whilst surveillance 
may represent security and symbolise 
hopefulness for some, for others it 
engenders feelings of vulnerability, 
uncertainty, abandonment (Simpson & 
Whyte, 2006) and anticipatory anxiety 
particularly when awaiting outcome 
of investigations (Simpson & Whyte, 
2006; Sjövall, Gunnars, Olsson, 
& Thomé 2011). Conventionally, 
patients attend outpatient face-to-face 
consultations with a medical clinician 
(surgeon or oncologist) but evidence 
suggests information needs are 
not always met, and appointments 
can initiate anticipatory anxiety, 
and general dissatisfaction (Beaver 
et al, 2010; Sjöval et al, 2011; 
Taylor, 2008). Also variability across 
providers and individual clinicians 
in terms of frequency, content and 
duration has been noted (Barravelli 
et al, 2009, Samarasinghe and 
Wiles, 2012; NHS East Midlands 
Cancer Network, 2011). Regularity of 
hospital visits may provide security 
whereas being told no curative 
treatment is available, and reducing 
frequency of surveillance and/or 
referral to other services or specialists 
can for some engender feelings 
of being ‘cast off’ by the cancer 
services (Jefford et al, 2011).
Much of the literature reviewed 
relating to follow-up is based on 
patients originally treated with 
‘curative intent’ but these delivery 
models may offer a template for 
service design for those experiencing 
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advanced disease. Living with the 
fear of recurrence appears as a 
major concern for patients and 
their families, understandably given 
that a proportion will experience 
further disease. Nurse-led face-to-
face appointments for symptom 
monitoring, eliciting concerns, and 
information provision have been 
introduced and well received in 
various settings (Beaver et al, 2010; 
Cusack & Taylor, 2010). Nurse 
specialists were consistently rated 
highly in terms of information giving 
and personalising the experience of 
care (Beaver et al, 2011; Cusack & 
Taylor, 2010; Ipsos MORI, 2012). 
A review examining the nurse 
specialist delivered telephone 
follow up (TFU) in CRC (Cusack 
& Taylor 2010) established TFU 
was acceptable to most patients 
and resource effective. Although 
advanced disease populations were 
not included in these studies their 
indings regarding acceptability to 
patients are of potential relevance. 
An area that requires attention is the 
development of the skills needed 
for telephone-based monitoring 
and patient education needs.
Various risk stratiied care pathways 
have been piloted in test communities 
(Ipsos MORI, 2012). Findings 
suggest barriers to change may 
be linked to cultural and resource 
issues in, and across, organisations. 
These could act as barriers to 
experimentation or reconiguring 
support to enable patients to 
become more self-managing 
(Ipsos MORI, 2012). Patient-held 
care plans, survivorship care 
plans, and treatment records have 
received attention as a mechanism 
to enhance communication, 
avoid patients becoming ‘lost in 
transit’ (Baravelli et al, 2009) and 
enable self-management and may 
become particularly important in 
any shift to self-care models.
An Australian study examined the 
potential of a patient-led, cancer 
coordination system using a web-
based platform (Sheeran, Milne, 
Holmes, Tidhar, & Aranda, 2012). 
This was developed and tested 
with patients with modest success 
as organisational barriers limited 
operability. During testing it became 
apparent that as a patient’s health 
status declined their ability to use 
the technology became more limited 
(Milne, Sheeran, Holmes, Tidhar, 
& Aranda, 2012). Although such 
systems have much potential to 
improve communication between 
patients, carers and primary 
and secondary care they have 
major operability challenges.
4A.4 Information needs
Understanding complex information 
regularly appeared in the literature 
as challenging for patients and 
their relatives (Appleton et al, 2013; 
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Jefford et al, 2011; Leighl et al, 2011) 
and dissatisfaction was frequently 
reported. This is unsurprising, as the 
cancer journey for any individual 
person will vary according to type, 
stage, treatment and response 
(King et al, 2010). The evidence 
indicates that information is 
inconsistent, fragmented and the 
patient voice not well represented 
(van Mossel et al, 2011).
Information-giving should be 
individualised, time sensitive and 
presented in ways that meet the needs 
and preferences of the patients, and 
signiicant others (O’Connor, Coates 
& O’Neill, 2010; van Mossel et al, 
2012). For example Morrison et al 
(2012) found patients expressed 
greater need for information 24 
months after diagnosis than earlier, 
in relation to recurrence, and 
recognition and understanding of 
long term complications of treatment. 
Areas identiied as particularly 
important to those with rectal cancer 
were the patients’ and families’ roles 
in, and preparation for investigations, 
treatment and ongoing care 
responsibilities, and psychosocial 
concerns such how to talk to friends 
and family about diagnosis and 
prognosis, relationships, body image 
and sexual functioning (O’Connor 
et al, 2010). A recent Australian 
mapping of CRC information 
resources (King et al, 2010) identiied 
gaps related to speciic transition 
points – diagnosis, treatment 
decision-making, discharge, primary 
care support – but makes no 
mention of any needs beyond the 
nebulous ‘post-treatment’ phase. 
A recent comprehensive review of 
CRC information needs research 
(van Mossel et al, 2011) identiied 
a number of notable omissions 
and/or areas with less evidence 
that need further scrutiny. These 
included dietary advice, radiation 
treatment, ‘coping’ and ‘how to do’ 
personal surveillance. Diagnosis and 
treatment are centre stage in the 
CRC information literature and what 
people wanted was time sensitive 
and individualised information that 
included ‘how to do’ guidance to 
support self-monitoring, self-care, 
decision-making and making the 
most of every contact with health 
services (King et al, 2010; O’Connor 
et al, 2010; van Mossel et al, 2012). 
Also van Mossel et al (2012) refer to 
a ‘Post-Treatment Information Package 
for People with Colorectal Cancer’ 
developed from their review which 
they were piloting (corresponding 
author contacted) which may have 
some useful content in the context 
of AAD in bowel cancer and 
transferability to a UK population.
A study involving a group of 
‘well enough’ CRC participants 
explored their preferences for what 
information should populate content 
of a peer support programme; they 
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identiied information about disease, 
treatments, side effects, how to be 
involved in decision-making, physical 
symptoms and palliative care as most 
important (Ieropoli, White, Jefford 
& Akkerman, 2011). Internet was 
the least preferred mode of delivery, 
but travel, carer responsibilities 
and having a stoma were reported 
as barriers to more participatory 
modes. Face-to-face group peer 
support was preferred as it afforded 
opportunities to share experiences.
Information related to ‘choice’ 
(Beaver et al, 2007), and speciically 
choice in advanced disease (Keating 
et al, 2010; Leighl et al, 2011), 
commonly involves discussion of 
chemotherapy and communication of 
clear, consistent relevant information 
(King et al, 2010). Clinician 
ambivalence about ‘best’ course of 
management may be discernible 
to patients, and how choices are 
presented appears to contribute to 
confusion and may inluence level 
of participation (Simpson & Whyte 
2006; O’Connor et al, 2010). 
An approach likely to facilitate greater 
patient involvement in decision-
making is the use of decision aids 
(DA) as these have the potential to 
improve knowledge, lower decisional 
conlict and increase levels of patient 
participation in decision-making 
(O’Connor et al, 2010; Stacey et al, 
2011). Including patients as active 
participants in such interventions 
can lead to improved knowledge, 
more accurate expectations, and 
choices that are well-aligned with 
their own values (Staley, 2009). 
One study relevant to this review 
by Leighl et al (2011) compared 
standard medical consultations with 
consultations involving use of a DA. 
They found that the DA (information 
booklet, audio/digital accompanying 
narration) increased patients’ 
understanding of prognosis, options, 
beneits and overall understanding 
without increasing anxiety.
An area that seems to receive less 
coverage in patient information needs 
research is dietary advice (Dunn et 
al, 2006; van Mossel et al, 2012). 
This is a striking omission given 
that there is good evidence that diet 
impacts on symptom management 
for CRC patients (Knowles et al, 
2013; Landers, McCarthy, & Savage, 
2012; NBCA, 2012) and diet is 
associated with increased relative risk 
of recurrence and mortality in Stage 
III CRC patients (Meyerhardt et al, 
2012). Van Mossel et al (2011) in a 
recently published comprehensive 
scoping review mapped the 
literature concerning information 
needs across the colorectal care 
continuum. Interestingly the 
cancer care continuum timeline 
they adopted categorised ‘post-
treatment (survivorship)’ and ‘end-
of-life’ but made no reference to 
AAD. They concluded that people 
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with CRC want information about 
managing bowel problems, diet and 
nutrition but that this interest is not 
mirrored in the research literature.
The beneits of exercise on wellbeing 
are well known, as are the positive 
effects it can have for those with 
active disease, and for survivors 
generally (Lowe, Watanabe, Baracos, 
& Courneya, 2009; Lynch et al 
2008a). For example a Canadian 
study designed to examine the 
relationship between physical activity 
and quality of life recruited a sample 
of cancer patients (n=11[22%] CRC) 
with a life expectancy of 3–12 months 
(Lowe et al, 2009). They found 
those undertaking physical activity 
(walking 30 minutes or more per 
day) had better self-reported quality 
of life. Also Meyerhardt et al (2006) 
found that people presenting with 
stages I-III CRC who increased their 
activity levels after diagnosis reduced 
their relative risk of recurrence 
and overall mortality. Exercise as 
a discrete information category 
appeared infrequently in studies, 
though it may be subsumed in 
general well-being advice and/
or linked with fatigue management 
(Thraen-Borowski, Trentham-Dietz, 
Edwards, Koltyn & Colbert, 2013).
On a cautionary note van Mossel et al 
(2011) highlighted that the research 
literature may provide coverage of 
an information need but that does 
not necessarily mean that people with 
CRC, or those signiicant in providing 
support (particularly partners 
and immediate caregivers) have 
expressed it as a need; it may merely 
represent the interest of researchers.
4A.5 Partners’/carers’ involvement 
in decision-making and support
A number of studies identiied that 
the needs and concerns of partners 
went unnoticed in contrast to those 
of the person with cancer (Williams 
& Bakitas 2012; Sjövall et al, 
2011; Taylor, 2008). Psychological 
symptoms of distress, underscoring 
the shared nature of a cancer, such 
as high levels of stress, anxiety, 
depression were reported as was 
reduced quality of life (McLean et 
al, 2008; Pereira, Figueiredo & 
Fincham, 2012). A number of studies 
(Altschuler et al, 2009; Ekholm et 
al, 2013; Fitzell & Pakenham, 2010; 
Ohlsson-Nevo, Andershed, Nilsson 
& Anderzén-Carlsson, 2012; Pereira 
et al, 2012; Sjövall et al, 2011; 
Williams & Bakitas, 2012) identiied 
unmet needs of carers, although 
relationships to the person with 
bowel cancer were not always clear 
and the term ‘carer’ or ‘caregiver’ 
often meant partner or spouse. 
Little literature emerged about the 
needs of sexual minorities in relation 
to CRC. Various reasons can be 
given for this invisibility such as the 
fact that sexual orientation data 
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is not routinely included in health 
records including cancer registrar 
data (Boehmer , Ozonoff & Miao, 
2011), the needs of this population 
may not be different, or perceived as 
different, and/or have yet to come 
to the attention of researchers.
Studies suggest that the concerns 
and anxieties of partners/carers 
were similar to those of patients. 
Partners found a cancer diagnosis life 
changing, that it altered relationship 
dynamics, could be socially isolating, 
and that systems for managing 
care often excluded them from 
receiving treatment and prognosis 
information or from involvement in 
decision-making (Ekholm et al, 2013; 
Ohlsson-Nevo et al, 2012; Sjövall 
et al, 2011; Williams & Bakitas 
2012). Yet much of the literature 
revealed expectations about roles 
carers could (and perhaps should) 
play: ‘maintain a shroud of silence’ 
about doubts and fears (Williams and 
Bakitas 2012:781), share the illness 
(Ohlsson-Nevo et al, 2012), become 
a caregiver (Sjöval et al, 2011), 
carry caregiving burden (Cotrim & 
Pereira, 2008), act as ‘cheer leader’ 
and strive to demonstrate sincere, 
unconditional regard (Altschuler 
et al, 2009). These ‘roles’ and the 
requirement to ‘stay in character’ 
understandably may become more 
demanding when living with the 
uncertainties of active and advanced 
disease. Reinforcing positive aspects 
of the role, open communication, 
and acknowledging the ‘social 
foundation’ of a caregiver’s life 
(Williams & Bakitas, 2012; Zulman et 
al, 2012) were identiied as successful 
strategies for developing resilience.
Higher levels of social support are 
generally associated with better 
patient and carer adjustment (Fitzell 
& Pakenham, 2010) but much of the 
attention has focused on the distress 
or burden experienced (Ekholm et 
al, 2013) – possibly to the neglect of 
more positive or afirming aspects 
of caregiving (Fitzell & Pakenham, 
2010; Williams & Bakitas 2012). 
There was limited literature examining 
how different gender, ethnicity or 
social inequality impacted on care 
burden or access to social support. 
Other studies (Altschuler et al, 2012; 
McLean et al, 2008; Ohlsson-Nevo et 
al, 2012; Pereira et al, 2012; Sjöval 
et al, 2011) examined (spousal) 
relationship functioning. Fitzell 
and Pakenham (2010) examined 
predictors of adjustment outcomes 
in CRC carers (84% partners/
spouses) and found stress appraisal, 
subjective interpretation of threat, 
and higher levels of social support 
as strongest predictors of carers’ 
adjustment. One Portuguese study 
found that when people with CRC 
were experiencing depression they 
were more likely to have partners 
who were also depressed and 
vice versa (Pereira et al, 2012).
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A number of studies described 
interventions designed to support 
people with CRC and their partners. 
For example McLean et al (2008) 
demonstrated a signiicant positive 
effect on couple functioning, and 
improvement in symptoms of 
depression (greater in patients) 
from an intervention using eight, 
once weekly sessions of Emotionally 
Focused Couple Therapy (EFT) 
with patients with advanced cancer 
(only 2 GI) and their partners. 
Zulman et al (2012) developed a 
supportive-educative programme 
(FOCUS) adapted from an in-
person to a tailored web-based 
format with end-users – people with 
CRC and carers. Operability and 
acceptability testing was largely 
positive even with older users and 
those with limited IT experience.
4A.6 Patient adjustment and 
concerns beyond initial treatment
Numerous descriptions of the period 
of CRC survivorship following initial 
treatment with curative intent discuss 
the omnipresence of cancer (Shaha 
& Cox, 2003) and living in a state 
of fearful watchfulness. Research 
identiies feelings of uncertainty 
(Sjöval et al, 2011) linked with fears 
of recurrence (Appleton et al, 2013; 
Dunn et al, 2006; Morrison et al, 
2012), and fears about withdrawing 
from the close attention of the health 
care system at end of treatment 
(Jefford et al 2011). People living 
with CRC may engage in a range 
of strategies to monitor their bodies 
(Taylor et al 2011, Morrison et 
al, 2012). McCaughan, Parahoo 
& Prue (2011) found that social 
comparison with other cancer patients 
could have very different meanings 
for different people. For some, it 
was experienced as helpful, while 
others found it so unhelpful that 
they actively avoided interactions 
with their fellow patients. These 
different responses have potential 
relevance to the types of support 
intervention that might be offered.
A number of studies examined or 
identiied ‘beneit inding’ in which 
the person with CRC recognised 
beneits or gains from their illness 
experience (Altschuler et al, 2009; 
Dunn et al, 2006; Simpson & 
Whyte, 2006; Rinaldis, Pakenham 
& Lynch, 2012). Beneit inding 
does not seem to be associated 
with higher overall quality of life 
measurement but is with some sub-
scales in some studies. However, 
a relationship was found between 
satisfaction with social support 
and beneit inding (Rinaldis et al, 
2012). Beneits identiied included 
heightened family risk awareness, 
participation in surveillance, 
recognition of what is important, 
and awareness of ‘being loved’.
RapidReview_Br0924_4.indd   34 13/02/2014   16:46
Supporting people with active and advanced disease: a rapid review of the evidence  35 
Some authors have suggested that 
CRC patients may become more 
socially isolated than other cancer 
patients, due to age, comorbidities, 
stigmatisation as a consequence 
of surgery (particularly ostomy) 
(Lynch et al, 2008b; Althschuler et 
al, 2009), side effects of treatment 
such as latus, faecal frequency and 
incontinence (Hamilton, Jackson, 
Abbott, Zullig & Provenzale, 2011; 
Ieropoli et al, 2011). Another US 
study reported patients with cancer of 
the rectum receive less professional 
social support than colon cancer 
patients (Hamilton et al, 2011). 
In the UK as all patients should 
be referred to a nurse specialist 
(stoma care nurse/colorectal nurse 
specialist) irrespective of treatment 
this is less likely. However, the recent 
audit identiied 10–15% of colorectal 
cases were recorded as not seen by 
a nurse specialist, the number could 
be higher as around 19% of all 
cases had the information missing 
(NBCA, 2012); this may be related 
to levels of emergency surgery.
The impact of ostomy on patients 
concerns, needs and quality of 
life outcomes varies across studies 
and does not appear to be directly 
associated with permanency of 
stoma (Hamilton et al, 2011; 
Hornbrook et al, 2011). The NBCA 
(2012) identiied that a signiicant 
number of patients had a stoma at 
12 months post initial surgery and 
this ‘should alert all teams to the 
on-going necessity for support in 
the community’ (NBCA, 2012: 9). 
Ostomy related dificulties included 
irritated peristomal skin, odour, 
noise and need to empty pouch 
frequently (Lynch et al 2008b). 
Restitution of anal defaecation 
can result in troublesome bowel 
function leading to decreased 
quality of life (Appleton et al, 
2013; Taylor and Morgan 2011).
4A.7 Transport, financial hardship 
and access to care
The establishment nearly two decades 
ago of specialisation, tumour site-
speciic multidisciplinary teams and 
treatment pathways has had a direct 
impact on survival for both colon 
and rectal cancer (Morris, Haward, 
Gilthorpe, Craigs & Forman, 2006), 
but for some may have inadvertently 
created new barriers to treatment 
and support access (Jones et al, 
2008). These include issues related 
to transport; for example, in a Welsh 
study of cancer outpatients (including 
CRC patients) car parking was one 
of the highest rated unmet needs 
(Morrison et al, 2012). For some CRC 
survivors experiencing distressing 
treatment-related complications 
– particularly faecal incontinence 
and urgency (Appleton et al, 
2013) – transport, parking and 
geography may be inluential in 
decision-making regarding treatment 
and out-patient attendance.
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 4A.8 Neglected areas
The dearth of literature relating 
to primary care was striking; only 
one paper identiied the role of 
GPs (Nazareth et al, 2008) and 
none related to other primary care 
professionals involved in supporting 
and managing people with long 
term conditions such as community 
matrons, practice nurses and district 
nurses. This is in spite of the fact 
that CRC is predominantly a disease 
of older people and experience of 
cancer in later life is mediated by 
other health (co-morbidity) and life 
challenges (including disability). 
The evidence we have reviewed 
shows that co-morbidities are often 
of concern to bowel cancer patients 
with active, advanced disease and 
also that they may struggle with the 
costs and practicalities of travel to 
specialist centres. There is surely 
a need for more involvement of 
community-based services for these 
patients, and for research to inform 
the development of interventions 
and evaluate their effectiveness.
It is apparent from this review 
that the bowel cancer experience 
is different for different people 
and may change over time for 
individual patients and those close 
to them. While interventions must 
of course be informed by evidence 
they must also be lexible enough 
to encompass variation in patient 
and carer needs and experiences. 
A ‘one-size its all’ approach will 
not necessarily gain universal 
approval irrespective of the evidence. 
The ability of service developers 
to tailor new initiatives to varying 
needs is hampered by the relative 
lack of research relating to certain 
groups in this population – especially 
ethnic and sexual minorities.
Colorectal cancer is a shared 
experience involving the patient, 
their partner and/or families and 
sometimes their wider social network. 
Those individuals who feel socially 
isolated and without an established 
support network undoubtedly require 
particular attention as there was 
some evidence this may impact 
on outcomes. For those who are 
well-supported, we need a better 
understanding of how services 
should engage with them and where 
appropriate involve them in support 
interventions. Information-sharing is 
a crucial area to address. The patient 
rightly should be ‘centre-stage’ 
and the focus of professionals, but 
partners and/or other signiicant 
caregivers need to be considered as 
supporting actors, not mere extras. 
Extending the theatrical metaphor, 
it was evident in our review that 
sometimes they are denied access 
to the script and often cut out of 
important scenes altogether.
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A number of articles, largely from 
the UK, described and tested novel 
approaches for follow-up and 
administration of chemotherapy, 
while others described different 
technologies that could be used as 
platforms for support, enhanced 
contact and surveillance. It must 
be recognised that interventions 
designed for research and the 
realities of care delivery may be 
different. Economic modeling of 
interventions is important, but 
successful real-world implementation 
requires a better knowledge of the 
enablers and barriers to adoption 
and assimilation (Greenhalgh, Robert, 
Macfarlane, Bate & Kyriakidou, 
2004). Healthcare services are 
complex and dynamic and service 
re-design inevitably brings a clash of 
cultures and norms (Iles & Sutherland, 
2001). Assuming what works in 
research can be transplanted and 
assimilated into other organisations 
would be naïve, yet few studies 
provided details of the change 
process needed to introduce different 
models of care. As identiied in the 
NBCA (2012) audit there is a need 
‘to explore the intricacy of processes 
of care and outcome that has a 
bearing on both the lives of patients 
that need palliative solutions and 
those that survive the consequences 
of altered bowel activity and changed 
body image’ (NBCA, 2012: 68). 
Our review would conirm this.
4B. Prostate cancer
Prostate cancer is the third most 
commonly-diagnosed cancer in 
the UK – and the most commonly-
diagnosed amongst men. In 2010 
there were 40,975 new diagnoses, 
and 10,721 deaths (CRUK 2013). 
Within the literature, the term 
‘advanced’ prostate cancer is most 
consistently used to refer to patients 
who have developed metastatic 
disease. Such patients may be treated 
with hormone therapy until the disease 
becomes hormone refractory and 
only palliative treatment is offered, 
which may include chemotherapy. 
A further category of relevance to this 
review is ‘locally advanced’ prostate 
cancer; these patients may or may 
not be suffering from symptoms and 
may be managed under ‘watchful 
waiting’ schemes or be in receipt of a 
range of treatment options, including 
surgery, radiotherapy and hormone 
therapy. Prostate-speciic androgen 
(PSA) levels are a key indicator used 
to assess disease progression.
The initial search based on the search 
terms and exclusion criteria described 
in the introduction produced 417 
abstracts. These were reduced in the 
next stage of the search process to 
a total of 65 articles; a further 16 
were identiied in supplementary 
searches resulting in a total of 81 
in the inal review. Thirteen items 
were identiied as ‘key articles’; 
summary details of these are given 
in Table 3, in the appendix.
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4B.1 Patient quality of life
We consider here evidence relating 
to Quality of Life (QoL) or Health-
related Quality of Life (HRQOL) in 
general, especially as measured 
by standard instruments for these 
constructs. Evidence focusing on 
speciic symptoms follows. The 
literature presents a complex picture 
of how prostate cancer impacts on 
men’s QoL. Korfage et al (2005) 
found that HRQOL of prostate 
cancer patients ive years after 
diagnosis was at least equal to that 
of the general population in US 
and Dutch studies. Nevertheless, 
there is considerable evidence for 
the deleterious effects of prostate 
cancer treatments on QoL, though 
these effects are highly speciic to 
particular treatments (Penson, Litwin 
& Aaronson, 2003; Sanda et al, 
2008). Where studies have compared 
QoL of men with advanced disease 
(usually deined as metastatic) with 
that of men with localised/early 
disease, they consistently show the 
former have lower QoL (eg Berglund 
et al, 2007). In a UK survey, Lintz 
et al (2003) found patients with 
advanced disease had lower scores 
on all quality of life areas (physical, 
role, emotional, cognitive and social 
functioning), compared to those with 
early/localised disease. Penson et 
al, (2003) argue that in men with 
advanced/metastatic disease, 
‘quality of life often becomes the 
primary desired outcome’ (p.1653).
An important issue in research 
examining quality of life in men 
with advanced prostate cancer 
is ‘response shift’. Response shift 
occurs in quality of life measures 
where respondents’ perception of 
what counts as ‘normal’ shift from 
the baseline as illness progresses. 
Thus symptoms that they would have 
rated as having a signiicant impact 
on quality of life early in illness 
may be discounted in later ratings. 
Korfage, Hak, de Koning, & Essink-
Bot (2006) argue that this occurs in 
men with advanced prostate cancer, 
where men accept urinary and bowel 
dysfunction as persistent side effects 
and do not consider these as part of 
their ‘health’. Consequently, when 
completing generic QoL measures, 
the importance of these symptoms 
may not be revealed. Faithfull, Cockle-
Hearne & Khoo (2010) point out that 
clinicians as well as patients may see 
urinary symptoms as an inevitable 
aspect of ageing and downplay their 
importance as a symptom of cancer 
and its treatment. In some respects 
this phenomenon might relect helpful 
adjustment to the realities of advanced 
disease, but it poses a challenge for 
researchers trying to accurately assess 
the long-term effects of prostate 
cancer and its treatment. One strategy 
to address this is to develop QoL 
measures targeted at speciic domains 
relevant to prostate cancer (eg Eton, 
Shevrin, Beaumont, Victorson & 
Cella, 2010; Ritvo, et al, 2005).
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There is evidence that health 
professionals’ perceptions of 
patients’ concerns may not always 
concur with the views of the patients 
themselves. A recent US-based 
study (Sonn, Sadetsky, Presti, & 
Litwin, 2013) compared patient and 
physician perceptions of quality of 
life in relation to the speciic areas 
of fatigue, pain, and sexual, urinary 
and bowel dysfunction. They found 
that these differed in all domains; in 
particular physicians ranked urinary 
and sexual dysfunction higher than 
the patients did, with the reverse true 
for fatigue and pain. Correspondence 
between patient and physician 
perceptions did not improve over 
time. While the reasons behind these 
discrepancies may be complex, 
including the reframing of what 
counts as ‘health’ as noted above, 
they do at least suggest there may 
be a need to improve training for 
doctors (and other HCPs) in eliciting 
concerns of prostate cancer patients.
4B.2 Patient experience: 
(i) Sexual problems, urinary 
incontinence and other  
physical symptoms
Sexual problems are prominent in 
the literature as a major concern for 
men with advanced prostate cancer; 
speciically loss of libido, erectile 
dysfunction and impotence linked to 
treatment (Carter, Bryant-Lukosius, 
DiCenso, Blythe & Neville, 2011; 
Galbraith, Hays & Tanner, 2012; 
Korfage et al, 2006; Lintz et al, 2003; 
Maliski, Rivera, Connor, Lopez, & 
Litwin, 2008; Rivers et al, 2011; 
van Andel et al, 2008). Issues of 
sexual function are often discussed 
in relation to their impact on couple 
relationships (Badr, Carmack & 
Cindy, 2009; Rivers et al, 2011) and 
to men’s sense of masculinity (Eton, 
et al, 2010; Galbraith et al, 2012; 
Galbraith, Fink, & Wilkins, 2011; 
Maliski, et al, 2008; Sanders, Pedro, 
Bantum & Galbraith, 2006; Song et 
al, 2012), and maintaining effective 
relationships is a major challenge for 
men with prostate cancer (Song, et 
al, 2012). In terms of sexual function 
issues, married men are two to three 
times more likely than single men to 
have some psychological needs in this 
regard (Lintz, et al, 2003) and sexual 
concerns are high on men’s agendas 
(Galbraith, Arechiga, Ramirez & 
Pedro, 2005). Notwithstanding low 
satisfaction in this area, Galbraith 
et al (2005) found that few men 
sought treatment. Men with advanced 
disease are more likely to report 
some need in relation to sexual 
dysfunction than those whose cancer 
was localised (Carter, et al, 2011; 
Lintz, et al, 2003). Even amongst 
older men sexual concerns are 
signiicant (van Andel, Visser, Hulshof, 
Horenblas & Kurth, 2003), though 
in the late stages of illness they 
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may decline in importance relative 
to other issues (Lindqvist, 2011).
Urinary incontinence is also a 
dominant issue of concern (Boonzaier 
et al, 2009; Carter, et al, 2011; Eton, 
et al, 2010; Faithfull et al, 2010; 
Korfage, et al, 2006; Lindqvist, 
2011; van Andel et al, 2008; Zhang, 
Strauss, & Siminoff, 2006). Faithfull 
et al (2010) found that 97% of men 
treated for prostate cancer reported 
lower urinary tract symptoms, half of 
which were classed as moderate to 
severe. Mols et al (2009) examined 
the long-term problems of men in 
the southern Netherlands ive to ten 
years post-diagnosis. They found 
48% of participants reported urinary 
incontinence, compared to 74% 
reporting erection problems and 14% 
bowel leakage. As has been found 
in other studies, treatment modality 
made a signiicant difference to 
speciic outcomes. (Note 18% of 
participants were identiied as stage 
TIII or TIV at diagnosis; staging at 
data collection is not reported, nor is 
the relationship between staging and 
extent of problems.) Other physical 
symptoms – which are frequently 
consequences of treatment rather 
than of the illness itself – include 
bowel control problems, pain and hot 
lashes, (Eton, et al, 2010; Lindqvist, 
2011; Lintz, et al, 2003; Steginga, 
Pinnock, Gardner, Gardiner, & 
Dunn, 2005). A further important 
effect of treatment is insomnia and 
sleep disorder/disturbance (Dirksen, 
Epstein & Hoyt 2009; Savard et al, 
2005). This may be linked to other 
symptoms – for instance, pain or hot 
lashes may disturb patients’ sleep. 
Sleep dificulties can cause or add 
to problems of fatigue and result 
in cognitive dysfunction (Engstrom, 
2005). The inter-connectedness of 
symptoms is very apparent here.
Evidence relating to the impact of 
the above symptoms speciically in 
the context of advanced disease is 
limited. Carter et al (2011) found  
that the physical symptoms of  
concern to men with advanced 
disease differed between those 
with hormone-sensitive and those 
with hormone-refractory prostate 
cancer, largely in relation to the 
effects of the different treatment 
regimes. While both groups suffered 
fatigue, the hormone-sensitive 
men were bothered by hot lashes, 
breast soreness and feelings of 
weakness, while the hormone-
refractory men complained of 
nausea and loss of appetite.
It is worth noting that while the 
literature typically distinguishes 
between physical and psychological 
symptoms, in reality they are often 
closely intertwined. For example, 
anxiety may affect sexual function, 
and pain is widely recognised to 
always include a psychological 
component (Keefe, Rumble, Scipio, 
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Giordano & Perri, 2004). This 
underscores the importance of 
an holistic approach to patient 
support. Lindqvist et al (2011) 
argue that we need to consider 
‘the symptom experience as an 
integrated whole’ (p.311); their 
study focuses on the meaning-
making engaged in by men with 
hormone-refractory prostate cancer.
(ii) Psychological symptoms
Psychological symptoms (in addition 
to those speciically related to 
sexual function) include depression, 
anxiety, and psychological distress 
(Couper et al, 2010; Dirksen, et al, 
2009; Lintz, et al, 2003; Purnell et 
al, 2011; Voerman et al, 2007). 
These symptoms are likely to be 
inter-related: for instance, Dirksen 
et al (2009) found signiicant 
relationships between depression, 
distress, and insomnia, with half of 
the men suffering clinically signiicant 
insomnia also experiencing clinically 
signiicant depression. Sharpley, 
Bitsika and Christie (2010) found a 
relatively high incidence of anxiety-
depression co-morbidity. Kahana 
et al (2011) argue that the complex 
impacts of long-term cancer 
survivorship in prostate, colorectal 
and breast cancer can be seen as 
post-traumatic transformations, 
which may have positive as well as 
negative aspects for survivors. A focus 
group study by Wallace and Storms 
(2007) found altered life perspectives 
of those men living with hormone-
treated advanced prostate cancer.
An Australian study by Couper 
et al (2010) found far greater 
psychological deterioration in the 
12 months after diagnosis for men 
diagnosed with advanced disease 
(ie metastatic) compared to early 
stage disease. The notion that the 
psychological consequences of 
prostate cancer may differ between 
early stage and advanced disease 
is supported in a study by Segrin 
and Badger (2010), which found 
that social support was positively 
related to depression in early 
stage but negatively in advanced 
disease. They suggest that a high 
level of social support may have 
been unhelpful to men with newly 
diagnosed localised disease because 
it served as an unwelcome reminder 
of their condition. In contrast, men 
with advanced disease are likely to 
experience distressing symptoms 
and side-effects of treatment and 
therefore require support from 
others in coping with these.
(iii) Spirituality
Within the palliative and supportive 
care literature spirituality has long 
been recognised as a key aspect of 
overall wellbeing (McClain, Rosenfeld 
& Breitbart, 2003); it is also relevant 
to survivorship (Vachon, 2008), 
including people with advanced 
disease. In a study of men with both 
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local/regional and metastatic prostate 
cancer, spirituality was positively and 
signiicantly associated with higher 
scores in all general and disease 
speciic QoL measures (Krupski et 
al, 2006). In a sample of 367 men 
with prostate cancer, 203 of whom 
were classiied as having advanced 
disease, Nelson et al (2009) found a 
small relationship between instrinsic 
religiosity and depression but a 
strong negative association between 
spirituality and depression. A main 
component in reducing depression 
when exploring religiosity and 
sprituality, is a sense of meaning and 
peace. Thus it could be important 
to develop men’s sense of meaning 
through activities/interventions 
(not exclusively religion-based) in 
order to achieve this. However, it is 
important to note that the association 
between religiosity and/or spirituality 
and QoL in cancer patients is 
complex, and caution is required 
in developing spiritual interventions 
(Hamrick & Diefenbach, 2006).
4B.3 Information needs of patients 
and partners
Information needs emerge strongly 
as an issue of concern for prostate 
cancer patients, including those 
with advanced disease – see 
especially, Carter et al (2011). 
They relate to all aspects of the 
experience and stages of the illness 
trajectory, from diagnosis though 
to end of life issues, though the 
side effects of illness and treatment 
are a particularly strong concern 
(see Boberg et al, 2003; Galbraith 
et al, 2012, Lintz et al, 2003).
The view that information needs 
persist and change beyond diagnosis 
and treatment of early-stage illness is 
stressed in several studies (Galbraith 
et al, 2012; Nanton, Docherty, 
Meystre, & Dale, 2009; Rozmovits 
& Zeibland, 2004; Vachon, 2008). 
For example, Nanton et al’s (2009) 
UK-based focus group study found 
that effective communication of 
information by health professionals 
was important to patients at very 
different stages in the illness 
trajectory, and that information-
seeking was part of an active coping 
strategy for some men. Grimsbo, 
Finset and Ruland (2011) highlighted 
a lack of information for patients after 
hospital treatment, describing them 
as feeling they were ‘left in a void’.
4B.4 Impact on partners and 
wider family
There is a fairly substantial amount 
of literature on how prostate 
cancer impacts on men’s partners, 
although this is overwhelmingly 
focused on heterosexual couples 
(Blank, 2005). The well-being of 
partners is recognised as important 
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both because of their crucial role in 
supporting men and because of the 
potential deleterious consequences 
for their own health. Rees et al (2005) 
found that partners actually had 
higher psychological morbidity than 
patients. Swore-Fletcher et al (2008) 
identiied clinically meaningful levels 
of psychological symptoms in female 
caregivers, which had a negative 
impact on their functional status 
and quality of life. The literature on 
wider family and friendship networks 
is much smaller. We identiied one 
paper that directly examined the way 
family members beyond spouses/
signiicant others were affected by 
a man’s prostate cancer (Segrin, 
Badger, & Figueredo, 2011). 
This suggested that wider family 
members were strongly affected by 
the patient’s prostate cancer, and 
that adult children were actually 
more depressed than spouses/
signiicant others. Note that this 
study (which also included families 
of breast cancer patients) does not 
state what proportion of prostate 
patients had advanced disease.
Several articles found in our search 
illustrate the interdependence in 
psychological wellbeing between 
men with prostate cancer and their 
partners (eg Galbraith et al, 2005; 
Harden et al, 2009; Ko et al, 2005). 
As with the Segrin et al (2011) article, 
cited above, these papers do not 
distinguish in their analyses between 
advanced prostate cancer patients 
and those at earlier stages (though 
all include some advanced patients 
in their samples). In contrast, Song 
et al (2012) directly compared dyads 
with patients in three different phases 
of illness: localised, biochemical 
recurrence and advanced. They found 
that open communication was highest 
in couples with advanced disease at 
baseline, and that it decreased over 
time for all groups. Furthermore, 
increased uncertainty about the illness 
was associated with decreased open 
communication, suggesting that 
when uncertainty is high, patients and 
spouses may be unsure what to say 
and be anxious not to raise concerns 
that would distress each other and 
themselves. This study points to 
the need for interventions to be 
designed to meet the speciic needs 
and challenges for communication 
relating to speciic phases of illness.
In the same RCT that was used as a 
source of data by Song et al (2012), 
Northouse et al (2007a) examined 
dyads of patients and spouses in 
relation to their psychosocial status 
and quality of life. Dyads were in 
three disease phase groups: newly 
diagnosed, biochemical recurrence 
and advanced (deined as metastatic 
disease at diagnosis or progression 
shown on diagnostic scans). 
They found that the psychosocial 
experiences of dyads at the same 
phase were similar, but they differed 
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from those at other phases. Dyads 
in the advanced phase had the 
highest levels of distress; these 
patients had the lowest physical 
quality of life and their spouses 
had the lowest emotional quality 
of life of the entire sample. The 
authors argue that this evidence 
supports the need for phase-speciic 
programmes of care for couples 
affected by prostate cancer.
4B.5 Psychosocial support and 
educational interventions
There are many accounts in the 
literature of psycho-social support 
interventions for men with prostate 
cancer, though not all report robust 
evaluations of their effectiveness. 
In common with other cancers, 
support groups have become a 
widely-used resource for prostate 
cancer patients, sometimes including 
their (female) partners as well. 
Other interventions include home 
or community-based educational 
and/or therapeutic programmes 
(eg Chambers, Foley, Galt, Ferguson 
& Clutton, 2012; Northouse et al, 
2007; Snyder et al, 2009), and 
telephone (Badger et al, 2011; Scura, 
Budin & Garing, 2004) and internet 
support services (Ruland et al, 2013). 
Interventions may combine several 
of these elements. While it is hard to 
come to general conclusions about 
such interventions – given the variety 
in format, content and evaluation 
methods – it does appear that they 
can be useful, especially in relation 
to meeting informational needs 
(Arrington, Grant & Vanderford, 
2005). There is some suggestion 
that female partners may ind 
them more useful in terms of social 
support than the men themselves 
(Northouse et al, 2007a).
Detailed studies of speciic 
psychosocial support groups 
have provided useful insights into 
their dynamics. Arrington et al 
(2005) found discursive practices 
and structural features of groups 
served to inhibit emotional support. 
Groups were predominantly 
focused on informational support. 
Bottorff et al (2008), looked at 
women’s participation in Canadian 
prostate cancer support groups 
and found they adopted roles 
congruent with stereotypically 
feminine positions: social facilitator 
(the most common), background 
supporter or cancer co-survivor.
When we focus on men with 
advanced disease, the evidence is 
much more sparse. We found very 
few interventions aimed speciically 
at this group, and in a fairly recent 
systematic review, Chambers, 
Pinnock, Lepore, Hughes and 
O’Connell (2011) highlight the 
paucity of research targeting men 
with advanced disease. Where 
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studies note the inclusion of men with 
advanced disease in interventions 
they generally do not present any 
speciic analyses for this group. 
We summarise below the main 
indings from the few studies that 
either relate to advanced disease-
speciic interventions or offer 
clear insights for these patients.
Chambers et al (2012) piloted an 
intensive mindfulness based cognitive 
therapy group intervention speciically 
for men with advanced prostate 
cancer based on a cancer speciic 
manual with additional, advanced 
prostate cancer-speciic components. 
They found that mindfulness-based 
cognitive therapy groups have utility 
for these patients with the potential 
to reduce anxiety, avoidance, and 
fearfulness of cancer recurrence. 
An unexpected inding was that the 
group experience and supportive 
exposure to other men with rapidly 
advancing disease enhanced 
acceptance of their condition. 
Thus there appeared to be a synergy 
between mindfulness and peer 
support in a group context.
Northouse et al (2007a) evaluated 
a psychosocial intervention for 
couples. The ‘FOCUS Programme’, 
originally devised for breast cancer 
patients and their families, consisted 
of three 90-minute home visits and 
two 30-minute telephone sessions 
delivered over a four month period. 
They looked at its impact on dyads 
where the patient was at initial 
diagnosis, biochemical recurrence 
or advanced phases of illness. 
Intervention patients showed lower 
uncertainty and better communication 
with spouses at four months from the 
start of the intervention, while spouses 
showed a wider range of psychosocial 
beneits, with some enduring to eight 
and 12 month assessments.
Boonzaier et al (2009) provide a 
useful account of the development 
of an Australian psycho-educational 
group intervention for men 
receiving radiotherapy for prostate 
cancer, delivered at pre-treatment, 
midtreatment, treatment completion 
and posttreatment stages. Although 
not focused particularly on men with 
advanced disease, an important 
feature that could be usefully applied 
in the advanced disease context was 
the modular design, whereby the 
group could opt to receive speciic 
modules to meet their emerging 
concerns. Note that Arrington et al 
(2005) report the development of 
separate topic-speciic subgroups 
within the ‘Man-to-Man’ support 
group programme.
The ‘Between Men’ programme 
was a seven-weekly psychosocial 
rehabilitation programme in Sweden, 
delivered by health professionals. 
Three different conditions were 
evaluated over a one year period: 
physical training alone, information 
alone, or a combination of the 
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two. Forty-two (20%) of the 211 
participants had metasteses at 
recruitment. An initial evaluation 
(in which results for advanced disease 
patients were not reported separately) 
found very high participant 
satisfaction with the programme; 
given a choice of programmes 
for the future, most participants 
opted for the information alone or 
combined programmes (Berglund, 
Petersson, Eriksson, & Haggman, 
2003). However, an evaluation of 
the effect of the programme on 
anxiety/depression and HRQOL 
found no signiicant improvements 
for any groups of patients. The 
authors suggest that the high drop-
out rate (c.20%) and the complex 
design may have had an impact 
on the ability of the evaluation 
to detect an effect. Future studies 
with simpler designs enabling 
higher power are recommended.
4B.6 Online and written 
informational and educational 
resources
The growth in the use of online 
resources by cancer patients is widely 
recognised, so it is unsurprising 
that the great majority of literature 
we found about informational 
resources related to online material, 
with several studies speciically 
including prostate cancer patients. 
(As with the material on psycho-
social interventions, discussion 
rarely highlights any speciic 
issues for advanced disease 
patients.) Examples of the kind 
of resources available include:
Macmillan Cancer Voices: 
opportunities.macmillan.
org.uk/p_homepage.aspx
Healthtalk online: healthtalkonline.
org/cancer/Prostate_Cancer
Prostate Cancer UK: 
prostatecanceruk.org
Prostate Cancer Foundation of 
Australia: prostate.org.au/
articleLive/pages/Advanced-
Prostate-Cancer.html
Prostate Cancer Foundation (US): 
pcf.org/site/c.leJRIROrEpH/
b.5699537/k.BEF4/Home.htm
Research suggests an interest in, and 
willingness to use, online resources 
amongst prostate cancer patients. 
For example, Shapiro et al (2004) 
found there was substantial interest 
amongst US prostate cancer patients 
in online resources. Pinnock, Jones, 
and The Education Committee 
of the Australian Prostate Cancer 
Collaboration (2003) describe the 
development of an Australian site for 
prostate cancer patients, which after 
two years was receiving 150,000 hits 
a month. Rozmovits and Ziebland 
(2004) used interviews and focus 
groups with UK breast and prostate 
cancer patients to explore what they 
wanted from informational websites. 
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They found a clear preference for 
non-commercial sites, and for those 
associated with recognised centres 
of excellence. Participants showed 
awareness of the potential pitfalls of 
internet-based health information, 
and would often look at a range of 
sites to help them make sense of 
a particular issue. In a Norwegian 
RCT, Ruland et al (2013) found 
improvements in symptom distress 
amongst breast and prostate cancer 
patients who accessed an internet-
based support system. Seale, 
Ziebland and Charteris-Black (2006) 
compared the ways the internet was 
used by men with prostate cancer 
and women with breast cancer. 
They found the men used it mainly 
for information-seeking about 
treatment and medical personnel 
while the women used it more for 
social and emotional support.
We only found one article reporting 
an intervention using printed 
informational material (Preyde, 
Hatton-Bauer, Cunningham & 
Panjwani, 2012). In this study, 50 
men evaluated a pamphlet on 
distress and supportive care for 
prostate cancer patients. Participants 
were recruited through attendance 
at a regional cancer centre in the 
US (Newly attending patients were 
excluded because of concerns 
about potential overburdening with 
information.) Participants found the 
pamphlet useful and easy to read, 
though made some suggestions for 
improvement and many felt they 
would have liked to have received the 
information earlier. Analysis does not 
separate out the views of patients with 
advanced disease. In their discussion, 
the authors note that less than half of 
their participants (mean age = 71) 
reported that they were interested in 
accessing the internet for information. 
Given the age proile of prostate 
cancer generally, we feel this is 
unlikely to be an attitude unique to 
this study and raises questions about 
the predominant focus on internet-
based resources noted above.
4B.7 Neglected areas
We found minimal evidence relating 
to the experiences and/or needs of 
ethnic minority men within the UK 
in relation to advanced prostate 
cancer. This is in spite of the fact that 
prostate cancer mortality rates are 
two to three times higher for men 
born in the West Indies and West 
Africa than for those born in England 
and Wales (Wild, Fischbacher, Brock, 
Grifiths & Bhopal, 2006). (Note also 
that for some ethnic minority groups 
Standardised Mortality Rates are 
lower than for the country as a 
whole – especially those from the 
Indian sub-continent and Eastern 
Europe.) Similarly, even looking at 
the international literature Chambers 
et al (2011) noted in their systematic 
review the neglect of minority 
groups (including ethnic minorities) 
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in psycho-social interventions for 
prostate cancer. The few studies of 
prostate cancer in African-American 
men certainly suggest there are 
distinctive issues for this group (Rivers 
et al, 2011) and it seems plausible 
that the same could be true for 
ethnic minority groups in the UK.
The conceptualisation of prostate 
cancer as a ‘couples’ disease’ has 
in many ways been beneicial in 
promoting interventions and research 
studies that address the condition 
in the context of relationships. 
However, it is perhaps responsible 
for the neglect of attention to the 
perspectives of single men. We only 
found one study that addressed the 
experiences of unpartnered men 
with prostate cancer. Kazer et al 
(2011) found that doctors played a 
particularly important role in decision-
making for these men in the absence 
of a partner with whom to discuss 
options. On the whole, the men were 
able to ind other sources of support 
and appeared to be self reliant in 
terms of emotional responses and 
managing day to day tasks of disease 
management. However, such men 
may need support in developing 
new relationships. There is clearly 
a need for more research to build 
on this single qualitative study.
A related issue is that the notion of 
a ‘couples’ disease’ almost always 
implicitly (and in empirical studies 
sometimes explicitly) deines the 
couple as heterosexual. Blank 
highlighted in 2005 the absence 
of research on gay, bisexual and 
transgender men, and our own 
search suggested there has been 
little change since then. We found 
very few studies referring to gay 
men and prostate cancer, and 
none of these looked particularly 
at advanced disease. Blank, 2005 
argues that some of the issues of 
signiicant concern may be different 
for gay men than heterosexual men, 
given differences in characteristics 
of sexual activity. They may have 
different patterns of social support, 
and may also face real or perceived 
prejudice from health professionals. 
Kleinmann et al (2012) agrees that 
the sexual preference and behaviour 
of men who have sex with men (MSM) 
renders them at risk of a reduced 
QoL. They cite a study just outside 
our date range by Fergus, Gray and 
Fitch (2002) who found that erectile 
dysfunction was especially of concern 
because anal penetration can require 
higher erectile function than vaginal 
penetration. In addition MSM were 
less likely to be in a monogamous 
relationship and more likely to have 
a new partner than heterosexual 
men – erectile dysfunction may be 
a major concern in this context.
While the literature certainly 
recognises physical symptoms such 
as pain and fatigue in men with 
advanced prostate cancer, these 
do not seem to receive as much 
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attention as urinary symptoms and 
sexual problems (and the psycho-
social impacts associated with 
them). Certainly the interventions we 
located that were of most relevance 
to AAD concerns tended to focus on 
these areas and/or general psycho-
social support issues. The recent 
indings by Sonn et al (2013) that 
doctors under-reported patient 
concerns regarding pain and 
fatigue and over-reported concerns 
regarding urinary and sexual 
problems supports this argument.
 
4C. Multiple myeloma
Multiple Myeloma (MM) is the 17th 
most common cancer overall in 
the UK. It has a higher incidence 
in men than women. In 2009 
there were 4,784 newly diagnosed 
cases, and in 2010 a total of 2,633 
deaths (CRUK, 2013). About three 
in ten patients are diagnosed with 
asymptomatic (or ‘smouldering’) 
myeloma. The progress of MM is 
usually classiied according to the ISS, 
based on levels of serum albumin 
and serum β2 microglobulin. Patients 
at the highest stage, III, are likely 
to have more severe symptoms 
and a worse prognosis than those 
at lower stages. However, as MM 
is incurable, and markedly varied 
in its progress, a clear deinition 
of ‘active and advanced disease’ 
is dificult to provide. Treatment 
aims to control the disease and 
commonly involves a combination 
of chemotherapy and steroids, with 
a range of other treatments to help 
manage symptoms. Younger and 
healthier patients may be offered 
stem cell transfusion (either from 
their own cells or a donor), though 
this group represent a minority of 
all MM patients – note that CRUK 
igures suggest 71% of newly 
diagnosed MM patients are aged 
65 and over (CRUK, 2013).
The initial search based on the terms 
and exclusion criteria described 
earlier produced 350 abstracts. 
Close scrutiny of the abstracts and 
for those not immediately rejected 
the full papers, plus the addition 
of items subsequently identiied, 
resulted in the inclusion of a total 
of 111 articles in the inal review. 
Nine items were identiied as ‘key 
articles’; summary details of these 
are given in table 4 (see appendix).
4C.1 Fatigue and pain
Numerous strategies are available 
for treatment of relapsed/refractory 
multiple myeloma dependent on age, 
prognostic factors, comorbidities, 
the quality and duration of response 
to prior therapy, and the number of 
relapses, and there currently exists 
no generally accepted standard 
treatment (van de Donk et al, 
2011). Rapidly evolving treatment 
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options mean that there is a new 
and growing need to recognise 
and manage the cumulative side-
effects of treatment in myeloma in, 
including those that may seem minor 
to doctors but which may have an 
important impact on patient quality 
of life (Mohty et al, 2010; Rome, 
Doss, Miller & Westphal, 2008; 
Smith, Bertolotti, Curran & Jenkins, 
2008; Tariman, Love, McCullagh 
& Sandifer, 2008). Lessons learned 
from late effects of cancer and its 
treatments conventionally applied 
to curable malignancies may be of 
increasing importance in multiple 
myeloma (Snowden et al, 2011).
Fatigue and pain appear to be 
particularly troubling symptoms which 
do not always appear to be well 
recognised or well managed (eg Hall 
et al, 2013; Molassiotis et al 2011a; 
Molassiotis et al, 2011b; Snowden 
et al, 2011; Wagner et al, 2012). 
Recently published guidelines for best 
practice provision of supportive care 
in multiple myeloma (Snowden et 
al, 2011) note that these symptoms 
may be under-recognised, and 
that it is important that healthcare 
professionals probe patients with 
regard to symptoms of pain and 
fatigue. In Molassiotis et al’s (2011b) 
study of everyday living with multiple 
myeloma, patients expressed 
resignation about symptoms and side 
effects including pain and fatigue 
issues, and so did not continue to 
express them as present symptoms in 
medical consultations. Note that there 
is a discrepancy in several studies 
(eg Harris et al, 2009; Wagner et 
al, 2012) between what doctors 
consider important to manage – 
primarily physical symptoms – and 
what is important to patients and 
their families, who have a more 
psychological focus. Thus, patients 
(and their carers) may feel it 
inappropriate to seek information, 
help and support about such issues 
from health care professionals.
4C.2 Information for patients: 
what to convey, and how
This area is often dificult in cancer 
generally, but there are particular 
issues that arise in relation to 
multiple myeloma. A key factor here 
is the very substantial increase in 
treatment options in recent years 
(eg Bird et al, 2011; Messori, 
Maratea, Nozzoli, & Bosi, 2011; 
Harousseau, 2010) though the 
trajectory of the illness, the nature 
of its symptoms and the side-effects 
of treatment also present challenges 
for information sharing (Lobb et 
al, 2009; Snowden, et al, 2011). 
Most recent guidelines highlight the 
need for information and support 
to be tailored to individual needs 
as far as possible (Bird et al, 2011). 
Patients and their signiicant others 
may be overwhelmed by information 
which they do not want and/or 
understand (eg Potrata, Cavet, Blair, 
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Howe, & Molassiotis, 2011; Maher 
& de Vries, 2011). When they do 
want to explore key information, 
they sometimes feel they do not have 
suficient opportunities to do so with 
health care professionals (eg Kelly 
& Dowling, 2011), or feel unable 
to ask questions or express their 
concerns due to fears they may be 
wasting health care professionals’ 
time (eg Maher and De Vries, 2011). 
Molassiotis et al (2011b) found that 
patients and carers had a general 
lack of expectation with regards to 
what help could be accessed, as 
well not wanting to ‘bother’ doctors 
with ‘emotional problems because 
that wasn’t their job’ or being fearful 
of overburdening ‘busy’ staff.
Education around the importance of 
medication adherence is highlighted 
as a concern, especially with regard 
to preventative drugs which do 
not have an obvious beneit to 
immediate patient well-being and 
which may have troubling side-
effects. For example, bisphosphonate 
treatment is known to have a 
signiicant effect in preventing and 
reducing skeletal complications in 
multiple myeloma (Aapro, Saad, & 
Costa, 2010; Terpos et al, 2009). 
Adherence to bisphosphonate 
treatment has a direct impact on 
the treatment’s eficacy in reducing 
or delaying skeletal complications. 
However, as a preventative treatment 
where positive effects may not 
be evident, and which can have 
troublesome side effects, patients 
need effective information and 
education to maximise adherence 
and compliance (Maxwell, 2007; 
McGrath & Holewa, 2010; Morris 
& Cruickshank, 2010). In a study by 
McGrath, Patton and Leahy (2009) 
patients reported that it was the 
exception rather than the norm to 
be fully informed regarding side 
effects of steroids. Similarly, there is 
a lack of education around the use 
of complementary and alternative 
medicines (Molassiotis et al, 2005).
4C.3 Supporting significant others
There is evidence that signiicant 
others play an important role in 
helping people live with advanced 
multiple myeloma (Kelly & Dowling, 
2011; Maher & de Vries, 2011; 
Molassiotis et al, 2011a; Molassiotis 
et al, 2011b; Potrata et al, 2011) 
and equally that the illness has an 
impact on close personal and wider 
social relationships (eg Cachia et al, 
in press). However, surprisingly few 
studies have assessed the experience 
of myeloma patients themselves 
(Potrata et al, 2011) and although 
signiicant others are repeatedly 
mentioned in this literature as playing 
an important role both in providing 
crucial support and in giving patients 
a reason to ‘carry on’ (eg Kelly & 
Dowling, 2011; Maher & de Vries, 
2011), there is very little work indeed 
which incorporates their perspective.
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In an interview study with 15 
myeloma patients (Potrata et al, 
2011), participants reported that 
family and friends were supportive in 
both practical and emotional ways – 
but were also responsible at times for 
causing patients’ substantial distress. 
Several patients in this study reported 
moving back in with family as a result 
of their condition as they could no 
longer afford mortgages or rents, 
and the authors suggest that friends 
seem also to play a far greater role 
than is generally realised, taking on 
potentially substantial practical and 
inancial burdens (this highlights the 
importance of using a wider deinition 
of ‘close’ or ‘signiicant’ other, rather 
than focusing solely on ‘carers’ in 
research). However, patients also 
reported that others could cause 
distress through well-meaning but 
poorly received enquiries after 
the patient’s health – the authors 
suggest this merits further attention 
as it could lead to social isolation 
or impaired social interactions at a 
time when patients need them most.
Two studies, both undertaken by 
Molassiotis and colleagues in UK 
settings (2011a, 2011b), focus 
on unmet supportive care needs 
reported by both myeloma patients 
and their informal caregivers. 
These papers provide the most 
comprehensive insight we identiied 
in the literature into issues faced by 
signiicant others. In both studies, 
fewer close others than patients 
participated – Molassiotis et al 
(2011a) reported that the primary 
reason given for non-participation of 
caregivers was ‘didn’t want to think 
about patient’s illness’ so indings 
may in fact under-represent the extent 
of problems faced by caregivers.
In the irst study (Molassiotis et al, 
2011a), 132 patients and 93 partners 
participated in a questionnaire 
study, completing a supportive 
care needs scale and a measure of 
anxiety and depression. The survey 
was conducted at a mean time of 
ive years post diagnosis. A greater 
proportion of partners than patients 
(a third compared to a quarter) 
reported unmet supportive care 
needs. Similarly rates of anxiety were 
higher amongst partners (48.8%) 
than patients (27.4%). A number of 
additional unmet supportive care 
needs were reported by partners 
only. These included a need for help 
to manage ongoing side-effects 
and/or complications experienced 
by patients as a result of treatment; 
provision of up to date information 
and information provided in a way 
that was understandable; the timely 
availability of local health care 
service available; emotional support 
for themselves; help in dealing 
with the changes that myeloma 
has caused to the patient. The 
authors conclude that long-term 
supportive care services should be 
available to provide support for 
both patients and their partners 
in relation to their unmet needs.
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The second paper by the same 
Manchester team (Molassiotis et al, 
2011b) reports on an interview study 
with 20 myeloma patients and 16 
informal caregivers (mostly spouses). 
Myeloma was found to have had a 
signiicant impact on emotional, role, 
social and work-related areas of life 
for both patients and their caregivers. 
No caregivers had been given any 
information directed speciically at 
them at any point, and there was 
low expectation amongst participants 
generally as to what information 
was available to caregivers. 
Overall, the emotional and practical 
cost of myeloma seemed greater 
for caregivers than for patients 
themselves, with patients seeming 
less engaged with their illness than 
caregivers. Caregivers were often 
providing practical and emotional 
support by neglecting their own needs 
and some caregivers felt unable to 
seek outside help or support as they 
felt the patient ‘would not allow it’.
Caregivers reported signiicant 
current and future concerns including 
dificulties in balancing their own 
lives and caring for the patient (social 
restrictions and negative impact 
on work and employment as a 
result of caring responsibilities were 
reported), a sense of helplessness 
when the patient was in pain and 
fears about how they would manage 
in the future when the patient 
became more unwell. Both patients 
and caregivers reported concealing 
stressful situations from the other in 
an effort to protect, though this was 
found to result in feelings of isolation. 
Caregivers also reported seeking 
out information about myeloma 
but iltering before relaying to the 
patient. Overall, the authors conclude 
that caregivers seem particularly 
vulnerable to high caring demands 
in myeloma, and that concerted 
action by healthcare professional 
should be directed towards this 
potentially overlooked group.
4C.4 Multidisciplinary working 
and the involvement of palliative 
care services
There are frequent references in 
the literature to the importance 
of multidisciplinary working, 
though much of this appears to be 
aspirational, rather than evidencing 
actual practice (Lobb et al, 2009; 
Snowden et al, 2011). Lobb et 
al (2009) found that unmarried 
patients with haematological 
malignancies including multiple 
myeloma expressed a greater unmet 
need for better communication 
amongst healthcare professionals 
in coordination of their care, and 
suggest that spouses may be playing 
an important but unacknowledged 
care co-ordination role. Molassiotis 
et al (2011b) suggest that continuity 
of care between specialist hospital 
care and care post-completion of 
treatments may need addressing. 
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In an interview study including 15 
British myeloma patients, Potrata 
et al (2011) found that ‘mobility 
dificulties’ were reported to cause 
patients considerable distress, but 
that these were inancial rather 
than physical problems – long 
waits for disability allowances from 
social services meant that patients 
were having to inance necessary 
equipment such as ramps and lifts 
in their homes themselves. This may 
point to problems in appropriate 
linked-up working between different 
services and service provision which 
may warrant further attention.
The fact that patients’ primary 
medical involvement is often 
with haematologists rather than 
oncologists may affect the other 
services they link in to, including 
contact with palliative care (Howell 
et al, 2010). Given that for the 
great majority of patients multiple 
myeloma is incurable, and that they 
may live with the condition for many 
years, involvement of palliative care 
services well before the end of life 
may be helpful (Manitta, Zordan, 
Cole-Sinclair, Nandurkar & Philip, 
2011; Epstein, Goldberg & Meier, 
2012). However, capacity issues 
for services and to some extent 
patient resistance may be a barrier 
to this (Snowden et al, 2011).
 
4C.5 Treatment strategies to 
minimise inconvenience to 
patients and families
Managing multiple myeloma 
(including the consequences of 
treatment) often requires medical 
interventions such as drug 
interventions (including oral or 
intravenous bisphosphonates) 
and repeated blood transfusions 
over extended periods of time. 
There is evidence that it might 
be feasible to deliver some of 
the required interventions in the 
home environment, and that this 
may have signiicant beneits for 
the quality of life of patients and 
families (eg Johnson et al, 2006; 
Kelly, Meenaghan & Dowling, 
2010; Meenaghan et al, 2010). 
Meenaghan and colleagues (2010) 
successfully trialled a consultant-
led nurse-coordinated service for 
home administration of bortezomib 
in Ireland. Johnson et al (2006) 
trialled a programme of Hospital in 
the Home Care following stem cell 
transplantation treatment in Australia. 
A nurse attended patients’ homes 
daily, administering IV medications, 
collecting blood samples, and 
providing red cell transfusions if 
necessary. Results suggest that, with 
adequate infrastructure support 
and rigorous patient selection, this 
model of care is safe and feasible. 
It is encouraging to note service 
providers’ concern to introduce 
new treatment paradigms in a 
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way which acknowledges the 
importance of patient preference and 
convenience (eg Morgan, Krishnan, 
Jenner & Davies, 2006), given the 
introduction of a number of novel 
and eficacious therapies for multiple 
myeloma over the last ifteen years.
4C.6 Availability of  
‘best practice’ treatment
There has been considerable 
controversy over access to new 
treatments for multiple myeloma in 
recent years. For example, the use of 
the proteasome inhibitor bortezomib 
in multiple myeloma was rejected by 
NICE in 2006, a decision that was 
reversed the following year following 
strong opposition from various 
groups (see Mehta & Low, 2007; Low, 
2007). Additionally, some treatments 
that may be very helpful are not 
yet widely available to all patients 
in the UK – for example, surgical 
procedures to manage vertebral 
compression fractures (Garland, 
Gishen, & Rahemtulla, 2011).
4C.7 Fear of recurrence
Multiple Myeloma is a condition 
characterised by periods of treatment 
and varying (shortening) periods 
of remission, which progresses 
at variable speed in different 
individuals (King & Morris, 2004). 
Understandably then, even the 
suspicion of relapse can trigger 
‘incredible new fear’ in patients 
(Durie, 2005). Literature on patient 
(and close others) experiences 
in multiple myeloma is generally 
limited compared to other cancer 
conditions and it is recognised that 
there is a need for more research 
into patient and family experience 
(Grundy & Ghazi, 2009). This is 
likely due to at least in some part to 
the fact it is only relatively recently 
that new treatment approaches have 
changed the traditional paradigm 
for management of the condition 
and that the survivorship agenda 
is thus a fairly recent concept 
in the context of myeloma.
Fears about future illness are, 
though, repeatedly emerge in what 
literature there is available as a 
primary concern for both patients and 
their close others. In an Australian 
questionnaire study of 66 patients 
with haematological malignancies 
including myeloma who had 
completed treatment, Lobb et al 
(2009) found that ‘help managing 
the fear of recurrence’ was one 
of the most frequently reported 
unmet needs. Younger patients 
were found to report greater needs 
for help in this respect. Cocks et al 
(2007) report on the development 
of a tool to assess quality of life 
in myeloma and identiied ‘future 
perspective’ as a key concern. In their 
phenomenological study of eight 
myeloma patients, Maher and de 
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Vries (2011) identiied a constant 
state of uncertainty (uncertain future, 
when will disease return, what will 
side effects of treatment be) as 
central – the need to control this 
pervaded all themes identiied.
Fears about future illness course are 
also emerging as a clear concern 
for those close to patients as well as 
patients themselves. Molassiotis et al 
(2011a) looked at reported unmet 
supportive care needs amongst 
both myeloma patients and their 
partners. Managing concerns about 
myeloma returning was reported 
as an unmet supportive care need 
by both patients and close others. 
Additionally, anxious and depressed 
patients reported double the number 
of unmet needs, and unmet needs in 
partners correlated with patient unmet 
needs. In a further paper reporting 
on interviews with myeloma patients 
and their informal caregivers about 
the effects of myeloma on their lives, 
Molassiotis et al (2011b) found that 
carers reported a number of fears 
for future, including concerns about 
how to manage when patients unable 
to care for themselves in the future. 
Similarly, patients reported that fears 
of relapse and uncertainty about the 
future could provoke intense anxiety 
about otherwise minor symptoms.
4C.8 Neglected areas
Rates of multiple myeloma are about 
twice as high in people from African 
and Afro-Carribean communities, 
yet this group is under-represented in 
research. This is seldom commented 
upon in the myeloma literature. 
It is known that those from ethnic 
minority backgrounds are less likely 
to participate in research and in 
randomised control trials generally 
(Hussain-Gambles, Atkin, & Leese, 
2004; Potrata, et al, 2011). Potrata 
et al (2011) are to be commended 
for their efforts to purposely recruit 
from ethnic minorities in an effort to 
redress this imbalance and recruited 
26.7% of their participants from 
ethnic minority backgrounds.
Older patients are under-represented 
in myeloma trials and research, 
despite higher myeloma incidence 
in this population. Our experience 
of reviewing the literature supported 
other authors’ conclusions that 
much of the research relates to 
the experiences of those myeloma 
patients who have undergone 
aggressive autotransplantation 
procedures (eg Potrata et al, 2011). 
As this tends to be an earlier stage 
treatment and is often not available 
to those of more advanced age, 
much of the literature does not 
relate meaningfully to those with 
‘active and advanced disease’. 
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Additionally, according to Molassiotis 
et al (2011a), this group of patients 
is not representative of MM patients 
overall as only a minority undergo 
blood stem cell transplants.
It was noticeable in the results of 
our search that some topics that 
are quite prominent in the literature 
for other cancers appeared very 
infrequently in relation to people 
with advanced multiple myeloma. 
These included in particular: inancial 
pressures and concerns, spirituality 
and sexuality/sexual dysfunction. 
The limited literature that we did ind 
suggests that such issues are relevant 
to multiple myeloma. Wagner et al 
(2012) found that doctors tended to 
focus solely on physiological disease 
manifestations when questioned 
in relation to factors impacting on 
quality of life in myeloma, whilst 
patients themselves additionally 
considered their mental health and 
sexual function as important in 
this context. Sherman, Simonton, 
Latif, Spohn & Tricot (2005) found 
that ‘negative religious coping’ 
(ambivalent or conlicted religious 
responses) was associated with 
signiicantly poorer functioning on 
measures of depression, distress, 
fatigue, mental health and pain in 
multiple myeloma patients preparing 
for stem cell transplantation treatment 
whilst neither general religiousness 
or positive religious coping were 
associated with outcome. Work and 
inancial problems for both patients 
and their families were mentioned by 
some authors (eg Bird et al, 2011; 
Potrata et al, 2011). Overall though, 
these issues are under-researched 
areas in comparison to other cancers.
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In this section we will relect on the 
process of carrying out this rapid 
review of evidence, and highlight key 
issues across the selected cancers that 
are relevant to the concerns of the 
NCSI AAD group speciically:
•	 recognising patient concerns
•	 patient and signiicant other 
information needs, involving and 
supporting signiicant others, issues 
of collaborative working
•	 the costs of advanced disease and 
support interventions
•	 neglect of minority perspectives.
Finally we will suggest priorities for 
future research and development.
5.1 Reflection on the  
review process
The topic of support for people 
affected by active and advanced 
disease proved a complex and 
challenging one on which to conduct 
an evidence review. There were two 
main reasons for this. Firstly, the term 
‘active and advanced disease’ is 
used very infrequently in the literature 
(as we saw in the introduction to this 
report); we therefore had to identify 
a range of other terms that might 
direct our search towards the kind of 
problems in which the NCSI group 
were interested. Secondly, in much 
of the literature that we found, the 
lessons relevant speciically to an 
AAD group were hard to extract 
because often researchers did not 
clearly distinguish the problems and/
or outcomes speciic to patients of 
interest to this review. We found 
numerous studies which identiied 
‘advanced disease’ patients as part 
of their sample, but which did not 
analyse data in a way that revealed 
whether and in what ways they were 
different from earlier-stage cancer 
patients. These factors inevitably 
created more ambiguity than would 
be ideal in applying the inclusion 
and exclusion criteria – hence even 
restricting ourselves to three cancers 
and to publications in the last ten 
years our initial search identiied over 
1,000 items.
The dificulties in carrying out this 
search are not only of technical 
interest with regard to the process 
of conducting an evidence review. 
Rather, we would argue that they 
relect ambiguity in how researchers 
and professionals understand the 
experience of AAD and uncertainty 
in how best to provide support 
to patients with such problems. 
For researchers and service 
developers, people affected by AAD 
may be ‘off the radar’, existing as 
they do in a liminal zone between 
recovery and supportive palliative 
care. On the research side, we would 
suggest that there are both pragmatic 
methodological and (perceived) 
ethical reasons for the relative lack of 
work clearly focused on those
5. Discussion
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affected by AAD. Patients with 
problems associated with AAD may 
be harder to recruit than those with 
earlier phase disease, or those who 
are in long-term remission, and 
their condition may make them 
more likely to drop out of a study 
after recruitment. Similarly, new 
interventions may be targeted at 
less ‘risky’ groups, resulting in AAD 
perspectives being absent or less 
prominent in related evaluation 
research – for example see the 
evaluation of telephone follow-up 
in CRC by Beaver and colleagues 
(Beaver et al, 2007, 2010, 2011). 
In terms of ethics, researchers may 
be reluctant to burden patients who 
are seriously ill with the demands 
of taking part in research, or may 
be prevented from so doing by 
health professional gatekeepers. 
Note though that there is evidence 
that even patients with very advanced 
disease welcome the offer to assist 
with research (Hardy, King & Firth, 
2012) and that such participation 
may have a positive impact on well-
being (Staley, 2009).
The essential messiness of this review 
process led us to taking a ‘bottom-up’ 
approach to organising our indings, 
focusing on issues relevant to AAD 
that emerged strongly in each cancer. 
We also noted what appeared to be 
signiicant gaps in each of the bodies 
of literature. The fact that some issues 
occur in relation to one (or two) of 
our selected cancers but not the 
other(s) does not mean they were not 
addressed at all in the latter; rather, 
it shows differences in the weight of 
recent (i.e last 10 years) research 
attention across cancers. To some 
extent this might relect different 
trajectories of advanced disease 
in the three cancers we examined. 
For example, fear of recurrence 
emerged strongly in our bowel cancer 
and multiple myeloma searches but 
was much less prominent in the AAD 
prostate cancer publications.
A inal point to note about the review 
process overall is that many of the 
articles we have included report on 
research and service evaluations 
from outside of the UK – especially 
from Australia, the US, Canada 
and (to a lesser extent) North-West 
Europe/Scandinavia. This relects 
the relatively small amount of UK-
based work looking directly at AAD 
issues. Although we excluded articles 
where we felt the cultural context 
seriously limited relevance to the UK 
situation, caution is still required in 
the conclusions drawn from studies in 
non-UK settings.
5.2 Key common issues  
across cancers
(i) Recognising patient concerns
There was evidence across the 
chosen cancers that professionals do 
not always recognise the concerns 
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that are priorities for patients with 
advanced disease. We would suggest 
there are two main reasons for 
this. Firstly, there is a tendency for 
professionals (and researchers) to 
look at patient experience through the 
lens of their own specialist interest. 
Thus Sonn et al (2013) showed 
that urologists relatively overstated 
prostate cancer patient concerns 
with urinary problems and sexual 
dysfunction and understated concerns 
with pain and fatigue. Harris et al 
(2009) and Wagner et al (2012) 
suggested that haematologists may 
underestimate the extent to which 
myeloma patients are troubled by 
psycho-social concerns. Secondly, 
patients with advanced disease 
may downplay some symptoms 
and treatment effects because they 
are resigned to them as ‘inevitable’ 
consequences of their condition 
and its management. We see this 
manifest in the phenomenon of 
‘response shift’ in quality of life 
measures for patients with longer-
term illness (Kahana et al, 2011).
(ii) Patient and significant other5 
information needs
The importance of clear, timely and 
properly targeted information for 
patients with cancer at all stages 
(and their signiicant others) has long 
been recognised by service providers 
and especially by charities such as 
Macmillan, Marie Curie and those 
dedicated to speciic forms of cancer. 
Nevertheless, this was highlighted 
as a continuing area of concern for 
patients and families affected by AAD 
across the three cancers we looked at. 
We found evidence for the potential 
effectiveness of interventions to 
enhance the provision and utilisation 
of information in a range of settings 
and formats (eg the use of decision 
aids for patients with advanced 
colorectal cancer considering 
chemotherapy; Leighl et al, 2011). 
Online information can be very 
useful, but given the age proile of 
most cancers (including those we 
looked at), other media remain 
important. The use of telephone 
contacts, either for routine follow-
up (eg Cusack & Taylor, 2010) or as 
part of a targeted educational and 
support intervention (eg Northouse 
et al, 2007a) can be a viable option, 
and well-designed printed materials 
remain valuable (Preyde et al, 2012).
(iii) Involving and supporting 
significant others
The importance of the support 
given to patients with AAD by 
family members and/or friends is 
recognised in all three cancers. 
Linked to this is the need to ensure 
signiicant others themselves are 
supported. The research evidence 
for the impact of advanced cancer 
on signiicant others is strongest for 
prostate cancer and least strong 
for myeloma. Furthermore, we 
found the same pattern in terms of 
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evidence for interventions involving 
and/or targeted at signiicant 
others. Although the evidence 
regarding the effectiveness of such 
interventions is patchy, there is 
enough to suggest that involving 
signiicant others alongside patients 
– as in some prostate cancer 
support groups – can be helpful 
for both parties (eg Chambers et 
al, 2011; McLean et al, 2008).
(iv) Issues of collaborative working
In all our cancers there was some 
degree of recognition that effective 
communication and collaboration 
between different professionals 
was necessary to ensure the best 
possible care and support for patients 
with AAD (though often this was 
aspirational rather than reporting 
on good practice). Not only the 
type of cancer but also the type of 
treatment patients were receiving 
could make a major difference to 
the range of services with whom they 
were in contact. For example, in a 
Canadian study, advanced prostate 
cancer patients who were hormone 
refractory were likely to receive 
care in regional centres with access 
to a wide range of professionals 
while those with hormone sensitive 
disease had little or no contact 
with professionals other than their 
urologists (Carter et al, 2011). 
There was recognition that hospital-
based medical specialists were not 
necessarily in the best position to 
understand and meet the support 
needs of such patients (Grundy & 
Ghazi, 2009). The potential role of 
nurses, especially advanced nurse 
practitioners, in addressing the needs 
of AAD patients was highlighted quite 
frequently, including in studies that 
reported interventions and/or service 
developments utilising their skills (eg 
Lindqvist, 2011; Meeneghan et al, 
2010). However, there was a lack 
of reference in this literature to the 
actual or potential role of community 
nurses – or even GPs – in supporting 
AAD patients.
(v) Costs of advanced disease and 
support interventions
Research on the costs of cancer 
includes that which focuses on the 
costs to patients and families of living 
with the consequences of disease 
and its treatment, and that which is 
concerned with wider economic costs. 
Within our selected cancer types, we 
found minimal information on either 
of these issues relating speciically to 
active and advanced disease. What 
little we found tended to be focused 
on personal costs – for instance, how 
transport issues impacted on uptake 
of services (eg Morrison et al, 2012). 
Much of this was in settings which 
differed in potentially important ways 
from the UK, such as the body of 
literature concerned with access to 
services in rural Australia (eg Corboy, 
McLaren & McDonald, 2011).
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The wider literature on the costs of 
cancer tends not to be speciic about 
stage of disease and often looks 
at cancer as a whole, or includes 
a selection of speciic cancers by 
convenience with little or no cancer-
speciic analysis (eg Sharp, Carsin 
& Timmons, 2012; Timmons, 
Gooberman-Hill, & Sharp, 2013). 
In a fairly recent review (Brooks, 
Wilson & Amir, 2011) most articles 
included focus on the costs of early 
stages of cancer – around diagnosis 
and initial treatment. It is reasonable 
to extrapolate from some of this 
general literature that some of the 
costs (both for patients/families 
and for the health service and 
wider economy) may be higher for 
patients living with active, advanced 
disease than those with earlier stage 
disease or in long-term remission. 
For example, AAD patients may 
be receiving ongoing treatment, 
may be unable to work or have to 
take signiicant time off from work, 
and may have multiple service 
involvement. There is unquestionably 
a need for future research looking 
at costs speciically associated with 
active and advanced disease.
(vi) Neglect of minority 
perspectives
In all our cancers, authors expressed 
concerns about the lack of research 
and/or interventions aimed at the 
support needs of minority groups 
– especially ethnic minorities but 
also gay men in relation to prostate 
cancer. (Sexuality is not considered in 
the bowel and myeloma literatures 
relating to AAD at all as far as we 
could see.)
5.3 Future research and 
development priorities for 
supporting patients with active 
and advanced disease
We will concentrate here on those 
areas for potentially fruitful future 
research and development that are 
likely to be relevant across many 
(if not all) cancer types.
1. There is a need to develop 
and evaluate methods of 
improving staff awareness of 
how patients and signiicant 
others are affected by active and 
advanced disease. Initiatives 
that involve professionals from 
across the range of disciplines 
and specialisms involved with 
particular cancers may be of 
value, as a way to counter the 
tendency for staff to look at 
patient concerns through their 
‘specialist lens’ as noted above.
2.  Further development of measures 
and assessment tools sensitive to 
quality of life issues for patients 
with active and advanced disease 
is needed.
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3.  We need to develop a better 
understanding of how different 
segments of the population of 
patients affected by AAD and 
their signiicant others understand 
and make use of information 
relevant to their circumstances. 
This includes looking at such 
factors as age, gender, ethnicity 
and education level in relation to 
different communication media 
and contexts. The timeliness 
of information to address the 
concerns of AAD patients should 
also be an important focus.
4.  Support interventions including 
signiicant others need to be 
developed and evaluated across 
all cancer types for those affected 
by AAD. Services generally 
should consider how they can 
better engage with patients’ key 
support networks. Some of the 
interventions we have identiied 
for prostate cancer patients and 
their partners may help inform 
intervention and service design, 
though the circumstances relating 
to speciic cancer types need to 
be borne in mind. Importantly, 
interventions and service 
developments need to look 
more widely at signiicant others 
than the rather narrow focus on 
heterosexual partners/spouses 
that dominates the prostate 
cancer literature. Similarly, the 
speciic needs of people from 
ethnic minorities affected by 
AAD – both patients and family 
caregivers – need more research 
to support targeted interventions.
5.  Collaborative working between 
professions, services and sectors 
is crucial to the support of people 
affected by AAD. New staff roles 
– or changes to existing roles – 
could play a part in facilitating 
this. Developments such as the 
Macmillan One-to-One projects, 
nurse-led telephone follow-up, 
and the role-out of the Midhurst 
approach to community palliative 
care may serve as exemplars, 
though it will be important to 
ensure that speciic issues relating 
to AAD are addressed.
6.  Research into the costs of cancer 
(personal, NHS and for the 
wider economy) needs to include 
more focused attention on the 
experiences of those affected by 
AAD and its treatment.
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Full reference Summary details
1 Craven, O., Hughes, C. A., 
Burton, A., Saunders, M. P., 
& Molassiotis, A. (2013). 
Is a nurse-led telephone 
intervention a viable 
alternative to nurse-led 
home care and standard 
care for patients receiving 
oral capecitabine? Results 
from a large prospective 
audit in patients with 
colorectal cancer. European 
Journal of Cancer Care 
229(3), 413–419.
Prospective audit (UK)
Comparison of three models (home nursing [n=83], nurse-led 
telephone [n=298] and standard care [n=81]) of care for patients 
receiving oral capecitabine (adjuvant and metastatic therapy) for 
colorectal cancer.
Longitudinal prospective evaluation comparing outcomes of nurse-led 
telephone support with data from previous randomised controlled trial 
(Molassiotis et al 2009).
Key indings:
•	 Improved toxicity symptom management with nurse-led telephone 
support compared to standard care and similar level as home care 
for some symptoms (vomiting and oral mucositis) but not others 
(diarrhoea and insomnia).
•	 Nurse-led telephone model also had low incidence of drug errors, 
less serious toxicities, low use of GP or unplanned hospitalisation.
2 Leighl, N. B., Shepherd, 
H. L., Butow, P. N., Clarke, 
S. J., McJannett, M., 
Beale, P. J., …Tattersall, 
M. H. (2011). Supporting 
treatment decision making 
in advanced cancer: a 
randomized trial of a 
decision aid for patients 
with advanced colorectal 
cancer considering 
chemotherapy. Journal of 
Clinical Oncology, 29(15), 
2077–2084.
Randomised trial (Australia)
Study of 207 patients with advanced colorectal cancer considering 
irst line chemotherapy. Random allocation to standard medical 
consultation or consultation with a decision aid (DA).
Patients receiving the DA intervention had:
•	 Greater increase in understanding of prognosis, options, risks and 
beneits, and higher overall understanding.
•	 Levels of anxiety, decisional conlict, treatment decisions and 
achievement of involvement preferences were similar irrespective  
of allocation.
Authors suggest DAs in advanced cancer could improve informed 
consent.
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3 Meyerhardt, J. A., Heseltine, 
D., Niedzwiecki, D., Hollis, 
D., Saltz, L. B., Mayer,  
R. J., …Fuchs, C. S. (2006). 
Impact of physical activity 
on cancer recurrence and 
survival in patients with 
stage III colon cancer: 
indings from CALGB 
89803. Journal of Clinical 
Oncology, 24(22),  
3535–3541.
Prospective observational study (USA)
Participants with stage III colorectal cancer (n=832) recruited into 
adjuvant chemotherapy trail. Instruments: Physical activity questions 
used to calculate metabolic equivalent task (MET) score. At six months 
a physical activity assessment undertaken.
Key inding:
•	 Physical activity after diagnosis associated with reduction in rates of 
recurrence and overall mortality.
4 N Nazareth, I., Jones, 
L., Irving, A., Aslett, H., 
Ramsey, A., Richardson, 
A., …King, M. (2008) 
Perceived concepts of 
continuity of care in people 
with colorectal and breast 
cancer – a qualitative case 
study analysis. European 
Journal of Cancer Care, 
17(6), 569–577.
In-depth case study using qualitative interviews (UK)
UK in-depth case study qualitative interview study with people with 
cancer (breast [n=12/3] and colorectal [n=9/4]) nominated close 
person and a primary and secondary health care professional (HCPs). 
Paper reports seven cases only.
Key indings:
•	 Patients who proactively take control are more likely to inluence 
continuity of care than those who depended on HCPs or 
disengaged.
•	 Patients who did not conide in their close person were less likely to 
get assistance with continuity or engage in care.
•	 Difference between clinicians’ and patients’ perspective of what 
constituted reasonable waiting times (appointments, investigations, 
results, etc).
•	 Communication was hampered by loss of letters, delay in transfer 
between secondary and primary care.
•	 Continuity enhanced by a long term relationship; clinical nurse 
specialists and GPs well regarded and perceived as facilitators of 
continuity of care.
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5 O’Connor, G., Coates, 
V., & O’Neill, S. (2010). 
Exploring the information 
needs of patients with 
cancer of the rectum. 
European Journal of 
Oncology Nursing, 14(4), 
271–277.
Survey (UK)
Participants with rectal cancer diagnosed in previous 18 months (only 
excluded if experiencing ‘very advanced’ disease). Adapted Toronto 
Information Needs Questionnaire (TINQ) administered to 42 people, 
40 responded.
Key indings:
•	 High level of information needs and not adequately met.
•	 Stoma care nurse specialists (SCNS) most valued source of 
information.
•	 Interpersonal communication with a HCP rated as preferred mode 
of communication. Information related to investigative tests least 
well met and treatment most well met.
•	 Lees satisied with information related to long-term physical, 
physiological and social aspects of the disease.
•	 Considerable variation suggesting need for individualised tailored 
information.
6 Pereira G. M., Figueiredo, 
A. P., & Fincham, F. D. 
(2012). Anxiety, depression, 
traumatic stress and quality 
of life in colorectal cancer 
after different treatments: 
A study with Portuguese 
patients and their partners. 
European Journal of 
Oncology Nursing, 16(3), 
227–232.
Field quasi-experiment (Portugal)
141 patients (62% males, 38% females) and 67 partners (39% males 
and 61% females) receiving surgery only, surgery with chemotherapy 
or surgery with radiotherapy. 48% had diagnosis >1 year and 29% 
for recurrence. Instruments: Patients: Hospital Anxiety and Depression 
Scale (HADS) and Quality of Life –Cancer (QOL–CA2); Partners: Beck 
Depression Inventory (BDI) State Trait Anxiety Inventory (STAI), Impact 
of Events Scale (IES–R).
Key indings:
•	 Patients receiving surgery alone and their partners had lower 
levels of psychological distress. Patients receiving surgery 
and chemotherapy had higher levels of traumatic stress and 
psychological morbidity.
•	 Patients who received surgery/chemotherapy and surgery/
radiotherapy had more treatment effects.
•	 Patients with a diagnosis > 1 year showed more global traumatic 
stress symptoms. Depressed patients more likely to have depressed 
partners.
•	 Patients reporting recurrence showed signiicantly higher levels 
of global traumatic stress but no evidence that this was treatment 
group related.
•	 Multi-modality treatment may engender greater/less psychological 
morbidity and reinforce need to assess patients and partners.
•	 Some evidence of post traumatic stress disorder (PTSD) reported 
particularly associated with recurrence.
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7 Sjövall, K., Gunnars, B., 
Olsson, H., & Thomé, 
B. (2011). Experiences 
of living with advanced 
colorectal cancer from two 
perspectives – inside and 
outside. European Journal 
of Oncology Nursing 15(5), 
390–397.
Qualitative interview study (Sweden)
13 participants with advanced CR cancer (deined as receiving 
palliative chemotherapy but not end of life with no cognitive 
dysfunction/cerebral metastases) and nine partners (spouse or  
living with).
Three categories emerged from patient participants: Being inside/
outside of the health system, striving for normality, value of life and 
vulnerability. Two categories related to partners: Living in an altered 
relationship and living in the shadow of the disease.
Key indings:
•	 ‘Belonging’ to the health system and using medical monitoring 
information to plan/evaluate was important – possible implications 
for follow up.
•	 Partners felt excluded from participation (by clinicians/sometimes 
patient) in care/treatment.
8 Thoresen, L., Frykholm, 
G., Lydersen, S., Ulveland, 
H., Baracos, V., Birdsell, L., 
& Falkner, U. (2011) The 
association of nutritional 
assessment criteria with 
health-related quality of life 
in patients with advanced 
colorectal carcinoma. 
European Journal of Cancer 
Care 21, 505–516
Analysis of data from terminated RCT (Norway)
Study involving people with colorectal cancer (Stage IV) who 
volunteered to participate in an RCT to compare dietary counseling to 
standard practice. (Trial terminated due to crossover between the two 
arms; patients followed up for two years or until death.)
Data collected at baseline and three months. Instruments: 
haemoglobin( (Hb), albumin and C-reactive protein (CRP), EORTC 
QLQ–C30 Version 3, anthropometric measurements (BMI), dietary 
intake (Energy intake using Diet 32 software), sarcopenia (CT Scan), 
nutritional risk score (NRS–2002), subjective global assessment (SGA) 
and cachexia deinition (EPCRC Cachexia).
Key indings:
•	 Weight loss at three months associated with reduced QoL, physical 
and social functioning and increased fatigue, pain and dyspnoea.
•	 Variation in number of people deined as cachexic dependent on 
measure used (EPCRC alone compared with EPCRC–SGA).
•	 QoL score constant in those whose weight was stable.
RapidReview_Br0924_4.indd   86 13/02/2014   16:46
Supporting people with active and advanced disease: a rapid review of the evidence  87 
Full reference Summary details
9 van Mossel, C., Alford, 
M., & Watson, H. (2011). 
Challenges of patient-
centred care: practice 
or rhetoric. Nursing 
Inquiry, 18(4), 278–289. 
doi:10.1111/j.1440–
1800.2011.00523.x
Scoping review
Examined information needs (psychological, medical, social, practical, 
inancial, nutritional and support) of people who have or have had 
colorectal cancer. 869 articles reviewed and 239 met the inclusion 
criteria. Categorised literature into 10 broad information themes (with 
82 sub-categories) and ive source categories and 19 subcategories.
Key indings:
•	 Only 64/239 (27%) contained views of people with colorectal 
cancer.
•	 Little literature written by dieticians or nutritionists or on 
radiotherapy.
•	 Treatment related information had greatest coverage followed by 
rehabilitation/post treatment Coping (10%) and minimal attention 
to surveillance health information and end-of-life concerns Post 
treatment ‘survivorship’ accounted for 42% but much was non-
stage speciic (62%).
10 Williams, A. L., & Bakitas, 
M. (2012). Cancer family 
caregivers: a new direction 
for interventions. Journal of 
Palliative Medicine, 15(7), 
775–783. doi: 10.1089/
jpm.2012. 0046
Qualitative interview study (USA)
Interviews with 135 caregivers of patients with colorectal or lung 
cancer; analysed using phenomenological methods. All patients 
receiving chemotherapy but no other information given about grade/
prognosis. Four themes emerged:
•	 Becoming a caregiver: related to hearing the diagnosis.
•	 New and altered relations: as a consequence of changed 
caregiving role/responsibilities relationship with self, patient, 
others and health care system changed. Feelings of social isolation 
as a consequence of new roles and lack of time with health 
professionals.
•	 Personal responses to caregiving: Various coping strategies 
described immersion in information and distraction in trivial 
activities to ‘stop thinking’; also remaining positive, optimistic and 
hopeful.
•	 Antecedent and social context: Caregiver responses were inluenced 
by previous experience and helpful/burdensome social network.
Authors suggest overlap of indings with caregivers of those receiving 
palliative care particularly the cheerleader role where ‘s/he must 
maintain a shroud of silence around all negative emotions and doubts’ 
(p781).
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Full reference Summary details
1 Carter, N., Bryant-Lukosius, 
D., DiCenso, A., Blythe, 
J., & Neville, A., J. (2011). 
The Supportive Care Needs 
of Men With Advanced 
Prostate Cancer. Oncology 
Nursing Forum, 38(2),  
189–198. doi: 
10.1188/11.ONF.  
189–198
Qualitative study (Canada)
Participants were 12 men with hormone-sensitive pc. 17 men with 
hormone-refractory prostate cancer.
Setting: outpatient cancer and urology clinics in central western 
Ontario.
Explored supportive care needs, priority needs, and suggestions for 
improvements to the delivery of care.
Participants identiied prostate cancer-speciic information and support 
to maintain their ability ‘to do what they want to do’ as priority needs.
2 Chambers, S. K., Pinnock, 
C., Lepore, S. J., Hughes, 
S., & O’Connell, D. L. 
(2011). A systematic 
review of psychosocial 
interventions for men with 
prostate cancer and their 
partners. Patient Education 
& Counseling, 85(2),  
e75–88.
Systematic review
Examined 21 studies (RCTs) dated 1999 to 2009.
Group cognitive- behavioural and psycho-education interventions 
appear to help promote psychological adjustment and QoL.
Coping skills training for dyads improved QoL for spouses.
Few interventions targeted at men with advanced cancer or at minority 
groups (by ethnicity or sexuality).
Trial quality low overall.
Noted limitations in research in terms of effective ways to improve 
men’s (and their partners’) adjustment to prostate cancer at any 
disease stage. There is an urgent need for interventions for men with 
advanced cancer and their families that focus on implications of 
advanced disease and the burden of caregiving for spouses.
Appendix
Key papers for bowel cancer, prostate 
cancer and multiple myeloma
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3 Cockle-Hearne, J., & 
Faithfull, S. (2010). Self- 
management for men 
surviving prostate cancer: a 
review of behavioural and 
psychosocial interventions 
to understand what 
strategies can work, 
for whom and in what 
circumstances. Psycho-
Oncology 19, 909–922
Evidence review on the best approaches for developing self-
management programmes.
Included RCTs from international literature, published over past  
12 years.
Key conclusions were:
•	 Self management viable/appropriate to provide health care 
solutions.
•	 Importance of targeting need and promoting motivation.
•	 Integration into clinical practice requires training, resources and 
commitment.
•	 Existing programmes tend to show lack of sustained effect over 
time.
•	 May be ‘teachable moments’ close to diagnosis and treatment.
•	 Needs differ across the disease trajectory and homogenous 
interventions may fail.
4 Eton, D. T., Shevrin, D. H., 
Beaumont, J., Victorson, 
D., & Cella, D. (2010). 
Constructing a conceptual 
framework of patient-
reported outcomes for 
metastatic hormone- 
refractory prostate cancer. 
Value in health, 13(5),  
613–623. doi: 10.1111/
j.1524– 4733.2010.00702
Interview and survey study (USA)
Interviews with 15 patients with metastatic, hormone refracatory 
prostate cancer (HRPC) – asked to identify most important symptoms, 
complications, concerns to consider when assessing the value of 
treatment.
Survey – 10 practitioners asked to determine/judge which outcomes 
endorsed by patients were attributable to the disease (symptoms) 
versus treatment (side effects). Classiications of each concern into: 
(i) disease, symptom, (ii) treatment side effect, (iii) both symptom and 
side effect or iv psychological concern.
Patients endorsed 11 concerns as relevant and important to HRPC.
Conceptual frameworks derived from patient-reported outcomes can 
be useful in assessment strategies: both for developing new measures 
or for choosing between existing ones.
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5 Galbraith, M. E., Hays, 
L., & Tanner, T. (2012). 
What men say about 
surviving prostate cancer: 
complexities represented 
in a decade of comments. 
Clinical journal of oncology 
nursing, 16(1), 65–72.
Qualitative, descriptive, narrative analysis of open-ended survey 
questions (USA)
135 participants provided answers to two open-ended questions.
Participants expressed the complexity of the experience. Sexual and 
other physical symptoms impacted their entire life. Acknowledgment, 
information, and help from others aided recovery.
Men needed more information and education about treatments  
and effects.
Conclusions:
•	 Unmet need for long term interventions with information being 
delivered during and beyond treatment.
•	 Future research needs to assess reactions of partners for a fuller 
picture.
•	 Clinical interventions should move towards a more integrated 
approach.
6 Kahana, B., Kahana, E., 
Deimling, G., Sterns, S., 
& VanGunten, M. (2011). 
Determinants of altered 
life perspectives among 
older- adult long-term 
cancer survivors. Cancer 
Nursing, 34(3), 209–218. 
doi: 10.1097/NCC.0b0 
13e3181fa56b0
Cross-sectional survey
288 survivors of breast, colorectal, and prostate cancer. 58% female, 
33% African American, and 67% white (mean age, 72.5 years).
Appraisals of the cancer experience as stressful/generating worry/
stigmatizing signiicantly associated with diverse PTT outcomes.
Posttraumatic transformations are related to the view that cancer is a 
continuing worrisome and stigmatising experience.
Nurses have a unique opportunity to discuss with patients potentially 
life-changing nature of the cancer experience. This type of discussion 
can enhance cancer survivors’ mental health.
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7 Kazer, M. W., Harden, J., 
Burke, M., Sanda, M. G., 
Hardy, J., Bailey, D. E., & 
PROSTQA Study Group. 
(2011). The experiences 
of unpartnered men 
with prostate cancer: a 
qualitative analysis. Journal 
of Cancer Survivorship: 
Research and Practice,  
5(2), 132–141.
Qualitative interview study (USA)
Semi-structured interviews with 17 men with prostate cancer,  
14 Caucasian and three Black, mean age 63.
Examined how men without partners (MwP) make decisions about  
PC treatment/manage treatment side effects/ obtain information  
and support.
Five themes emerged: going it alone; diagnosis and prostate cancer 
treatment decision-making; sources of information and support; 
aftermath of prostate cancer; coping strategies.
Conclusions:
•	 MwP may need to be identiied in order to ensure they are coping/ 
can access support.
•	 MwP may have enhanced coping compared to partnered men.
•	 MwP may need support in new relationships and managing  
side effects.
•	 Role of physicians in decision making process of MwP is unique.
8 Korfage, I. J., Hak, T., de 
Koning, H. J., & Essink-
Bot, M.L. (2006). Patients’ 
perceptions of the side-
effects of prostate cancer 
treatment – a qualitative 
interview study. Social 
Science & Medicine, 63(4), 
911–919.
Qualitative study (Netherlands)
Interviews with 33 patients, six years after primary treatment.
Primary prostate cancer treatment often results in suboptimal urinary, 
bowel and/or sexual function, yet patients often report high HRQoL 
scores. Discrepancy raises the question of the meaning of side effects 
to patients.
Found participants did not take such dysfunctions into account when 
completing QoL measures because saw these as inevitable part of 
their lives with prostate cancer – producing a ‘response shift’ in QoL 
measures through a change in men’s ‘internal standards’.
Can be seen as positive adaptation – normalisation of changed lives. 
BUT may distort QoL measures in research and assessment, and could 
affect screening and treatment decisions based on such measures.
9 Lindqvist, O. (2011). 
Living with bodily changes 
in hormone- refractory 
prostate cancer. Seminars in 
Oncology Nursing, 27(4), 
309–316.
Qualitative study (Sweden)
Interviews with 20 men, aged 46 to 80 years.
Bodily changes and skeletal metastases were extensive; physical 
burden profoundly affected men’s QoL.
Results support paramount importance of symptom alleviation and 
also of dialogue between patients and health care providers.
Oncology nurses well placed to help men and partners in obtaining 
necessary information to cope with challenges.
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10 Lintz, K., Moynihan, C., 
Steginga, S., Norman, 
A., Eeles, R., Huddart, 
R., ...Watson, M. (2003). 
Prostate cancer patients’ 
support and psychological 
care needs: Survey from 
a non- surgical oncology 
clinic. Psycho-Oncology, 
12(8), 769-783. doi: 
10.1002/pon.702
Cross-sectional survey (UK)
Participants: 210 men with localised (69%) or advanced (metastatic: 
30%) disease. Mean age 69.7 years. Recruited from specialised tertiary 
referral cancer centres.
Found signiicant unmet psychological and health systems/information 
needs. Most commonly reported were ‘fears about cancer spreading’ 
(44%), ‘concerns about the worries of those close to you’ (43%) and 
‘changes in sexual feelings’ (41%).
Overall needs were well met in the domain of patient care and 
support.
Men with advanced disease (ie metastatic) scored lower on most 
QoL categories, and had greater levels of depression than those with 
localised disease.
11 Northouse, L. L., Mood, D. 
W., Montie, J. E., Sandler, 
H. M., Forman, J. D., 
Hussain, M., … Kershaw, 
T. (2007a). Living with 
prostate cancer: patients’ 
and spouses’ psychosocial 
status and quality of 
life. Journal of Clinical 
Oncology, 25(27),  
4171–4177.
Randomised clinical trial (USA)
Spouse dyads, randomised to control group (n=123) or intervention 
group (n=112).
Intervention consisted of a family-based educational and support 
programme, based on the FOCUS Program for breast cancer but 
modiied for prostate. Participants received ive sessions – three at 
home and two by telephone – delivered by specially trained nurses. 
Outcome data were collected at four month, eight month and 12 
month intervals from baseline (start of programme).
At four months, intervention patients were signiicantly less uncertain 
and reported better communication with spouses than controls. 
Intervention spouses showed signiicantly better scores than controls 
on communication with partner, quality of life, and self-eficacy, and 
signiicantly lower negative appraisal of caregiving, hopelessness, 
uncertainty and symptom distress.
At eight months spouses in the intervention had better physical 
Qol than controls (but not mental QoL), lower uncertainty, better 
communication and fewer problems related to the patient’s urinary 
incontinence. At 12 months, the signiicant positive differences in 
communication, physical QoL, and self-eficacy continued. Intervention 
spouses showed signiicantly greater use of active coping than 
controls at 12 months (though this had not been apparent at earlier 
measurement points).
There were no signiicant beneits for intervention patients over 
controls at eight or 12 months. Study provides good evidence for the 
value of such interventions in terms of the health and well-being of 
spouses of men affected by prostate cancer.
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12 Song, L., Northouse, L. L., 
Zhang, L., Braun, T. M., 
Cimprich, B., Ronis, D. L., & 
Mood, D. W. (2012). Study 
of dyadic communication in 
couples managing prostate 
cancer: a longitudinal 
perspective. Psycho-
Oncology, 21(1), 72–81.
Secondary analysis of longitudinal data from RCT (USA)
Based on data from the same RCT as described above in Northouse  
et al (2007).
Examined the patterns of change in communication between couples 
and which factors affected this over time, including phase of illness 
(localised, biochemical recurrence, advanced).
Within dyads, men and their partners reported similar levels of 
open communication at time of diagnosis. Patients and spouses with 
localised cancer reported less open communication at diagnosis than 
those with recurrent or advanced. However, levels of communication 
decreased over time regardless of phase of illness at diagnosis.
Levels of communication were higher where dyads reported higher 
social support, lower uncertainty and fewer hormonal symptoms.
A lack of open communication may compromise men’s relationship 
with their partners and their psychological adjustment to prostate 
cancer. Such communication tends to decline over the illness trajectory, 
despite the fact that in advanced cancer there is an increasing need for 
couples to share thoughts, feelings and information about treatment 
decisions and caregiving needs.
Interventions could facilitate couples’ interaction and mutual support 
during survivorship, with potential beneits to both parties.
13 Sonn, G. A., Sadetsky, 
N., Presti, J. C., &Litwin, 
M. S. (2013). Differing 
perceptions of quality of 
life in patients with prostate 
cancer and their doctors. 
The Journal of Urology, 
189(1), S59–S65.
Prospective study
Analysis of two national cohorts of a total of 1366 men treated for 
localised PC. 15% had PSA scores of 10.1–20 and 5% scores over 20.
The study compared and contrasted patient and physician perceptions 
of quality of life in relation to: fatigue, pain, sexual, urinary and bowel 
dysfunction over time.
While urinary problems and sexual dysfunction were major concerns 
for patients, their relative importance was over-stated by physicians in 
comparison to the patients themselves; in contrast, physicians relatively 
understated patient concerns with pain and fatigue. Correspondence 
in perceptions did not improve over time.
It is important for all levels of HCPs to be trained in acknowledging 
and addressing impairments in QoL from prostate cancer and its 
treatments.
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1 Bird, J. M., Owen, R. G., 
D’Sa, S., Snowden, J. 
A., Pratt, G., Ashcroft, J., 
...UK Myeloma Forum. 
(2011). Guidelines for the 
diagnosis and management 
of multiple myeloma 
2011. British Journal of 
Haematology, 154(1),  
32–75. doi: 
10.1111/j.1365–
2141.2011.08573.x
Best practice guidelines (UK)
Produced by the British Committee for Standards in Haematology in 
conjunction with the UK Myeloma Forum (UKMF). Intended to be used 
in conjunction with Snowden et al (2011) guidelines for supportive 
care.
Recommendations for clinical practice are provided under the 
following headings. These include management of refractory and 
relapsed myeloma.
2 Cachia, E., Eiser, C., 
Ezaydi, Y., Greenield, D. 
M., Ahmedzai, S. H., & 
Snowden, J. A. (In Press). 
Living with advanced but 
stable multiple myeloma: 
A study of the symptom 
burden and cumulative 
effects of disease and 
intensive treatment on 
health-related quality of 
life. Journal of Pain and 
Symptom Management.
Survey (UK)
(N = 32, median age 55 at Dx, 61 at assessment.)
All had had haematopoietic stem cell transplantation and subsequent 
treatment for at least one episode of progressive disease.
Measures of HRQoL, pain, peripheral neuropathy, concerns. Clinical 
history, treatment and current meds from case notes. Serum IL-6 and 
TNF- also measured.
Despite disease stability, intensively-treated long-term myeloma 
survivors have signiicantly compromised HRQoL associated with 
symptom burden. Speciic issues include:
•	 Progressive work disability and early retirement. Restricted social 
and physical activities.
•	 Fatigue and pain affecting physical functioning.
•	 Concerns re loss of independence, shortened life expectancy 
(especially re life with partner).
•	 Concerns re pain and sexuality positively correlated with concerns 
re rejection.
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3 Grundy, M., & Ghazi, 
F, (2009). Research 
priorities in haemato-
oncology nursing: results 
of a literature review and 
a Delphi study. European 
Journal of Oncology 
Nursing, 13(4), 235–249.
Literature review and Delphi study (UK)
Lit. rev. 1996–2008, 90 articles included. Delphi questionnaire to 
1444 UK nurses working in ield.
Final list of 33 research priorities identiied. The following areas 
relevant to AAD are identiied as under-researched/requiring more 
attention:
1 Studies including older participants and those with a poor 
prognosis.
2 Need for more longitudinal/prospective research examining patient 
experience and QoL.
3 Patient experience research linked to testing of nursing 
interventions. 
4 Research relating to employment/return to work.
5 Side effects. Patients usually experience multiple side effects which 
are often inter-related, so exploration of ‘symptom clusters’ may be 
more useful for future research.
6 Impact on family/signiicant others, including inancial hardship. 
Almost nothing on caregivers whose relative receiving a treatment 
other than SCT.
7 Organisational issues (context of care, role development and nurse 
led care). Particularly important to develop home-based care and 
follow-up.
4 Howell, D. A., Roman, 
E., Cox, H., Smith, A. G., 
Patmore, R., Garry, A. C., 
& Howard, M. R. (2010). 
Destined to die in hospital? 
Systematic review and 
meta-analysis of place of 
death in haematological 
malignancy. BMC Palliative 
Care, 9(9), 1–8.
Systematic review and meta-analysis
Haematological (but not MM) speciic.
Patients with haematological cancers more than twice as likely to die 
in hospital as those with other cancers. Why? Potential contributory 
factors identiied include:
•	 The complex transition from an active or curative approach to a 
palliative approach to care – a transition which is not always clear 
in haematology.
•	 The increasing number of salvage therapies, resulting in continued 
treatment even in the very late stages of disease – may give rise to 
sentiments of denial or the continued hope of a response, both in 
patients and practitioners.
•	 Close relationships between patients and haematology teams 
may result in less knowledge of and access to community-based 
palliative care services.
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5 Meenaghan, T., O’Dwyer, 
M., Hayden, P., Hayat, 
A., Murray, M., & 
Dowling, M. (2010). 
Home administration of 
bortezomib: making a 
difference to myeloma 
patients’ lives. European 
Journal of Oncology 
Nursing, 14(2), 134–136.
Trial of home administration of bortezomib (Spain)
Drug requires frequent IV admin (usually twice a week for two 
consecutive weeks with a 10 day rest period). Admin takes only 10 
seconds but patients can spend up to six hours per visit in day unit 
(and often have to travel long distances to get there).
Haematologist identiied suitable patients (high functioning, compliant 
with other meds). Home admin co-ordinated by haematology 
specialist nurses. At home visits, routine bloods and physical 
assessment also undertaken and patients questioned about side 
effects.
Once drug reconstituted, has to be delivered to patient within an 
eight hour window so requires good co-ordination between hospital 
pharmacy and home admin nurses.
Good communication between nurse co-ordinating service and home 
admin nurse also vital to facilitate prompt reporting of any side effects.
Successful pilot. Planned to enrol 10 – enrolled 23. Excellent patient 
feedback. No serious side effects. Vast majority maintaining treatment.
6 Molassiotis, A., Wilson, 
B., Blair, S., Howe, T., 
& Cavet, J. (2011a). 
Unmet supportive care 
needs, psychological 
well-being and quality of 
life in patients living with 
multiple myeloma and 
their partners. Psycho-
Oncology, 20(1), 88–97. 
doi: 10.1002/pon.1710
Cross-sectional survey (UK)
132 patients and 93 partners; all patients at least one year post 
treatment (Dx). Focus of study on longer term needs in MM survivors.
Sought to identify nature and range of unmet supportive needs and 
QoL levels amongst MM patients and their partners.
•	 a quarter of patients and a third of partners reported unmet 
supportive care needs.
•	 presence of side effects of treatment was the single most important 
variable in predicting unmet supportive care patient needs. Unmet 
needs in partners correlated with patient unmet needs.
•	 27.4% of patients reported anxiety and 25.2% depression; amongst 
signiicant others.
•	 48.8% reported anxiety and 13.6% depression. Anxious/depressed 
patients had more than double unmet needs than non-anxious/ 
depressed patients.
•	 Note that fewer partners then patients recruited – primary reason 
for non- participation ‘didn’t want to think about partner’s illness’ – 
so this may in fact under-represent extent of problem.
•	 Given that 35.9% of patients report pain ‘currently’, suggests that 
pain management is suboptimal.
•	 Long term supportive care should provide support to both patients 
and their partners. Need to optimise symptom management to 
improve patient QoL.
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7 Molassiotis, A., Wilson, 
B., Blair, S., Howe, T. and 
Cavet, J. (2011b). Living 
with multiple myeloma: 
experiences of patients and 
their informal caregivers. 
Supportive Care in Cancer, 
19, 101–111.
Qualitative interview study (UK)
20 MM patients and 16 informal caregivers (usually spouse) exploring 
the experience of myeloma ive years after treatment (Dx).
•	 Signiicant impact of MM reported on emotional, role, social and 
work related areas of life for both patients and caregivers.
•	 Caregivers were providing support to patients (practical and 
emotional) almost exclusively, and often at the expense of their own 
needs.
•	 Both parties concealed stressful situations from the other in an 
attempt to protect, but this resulted in isolation.
•	 Findings from patient interviews: 1) Current and future concerns 
– frustration at current limitations imposed by illness on everyday 
activities; having to rely on others and related guilt; dificulty in 
accepting change in self-image; fears of relapse and uncertainty 
about future. 2) Effects of myeloma on daily life – fatigue and 
pain as most troubling symptoms; long term effects of treatment 
still impacting on life (though not currently undergoing treatment). 
3) Practical, functional and emotional coping: practical – use of 
aids (sometimes refused because of embarrassment); information 
– some eager to gather, others preferred to avoid); covering 
(concealing) and protecting others reported as coping strategy.  
Not wanting to bother health care professionals with concerns.  
4) Unmet needs – continuity of care especially when initial 
treatment inished; a sense of resignation about symptoms that 
could not be managed well – patients stopped mentioning at 
consultations. Not wanting to bother doctors with emotional 
problems. Support groups unpopular.
•	 Findings from caregiver interviews: 1) Current and future 
concerns – dificulties balancing own lives and caring for patient; 
helplessness when patient in pain; fears for future, when pats 
unable to care for themselves in any way. 2) Effects on daily 
life – social restrictions; impact on own working life. 3) Practical, 
functional and emotional coping – sense of ‘duty’ attached 
to caring – not perceiving self as ‘carer’; iltering information 
to patients. 4) Unmet needs – lack of information speciically 
designed for carers; found it dificult to speak to doctors; sometimes 
did not understand info given by HCPs due to use of jargon.
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8 Potrata, B., Cavet, J., 
Blair, S, Howe, T. and 
Molassiotis, A. (2011). 
Understanding distress and 
distressing experiences in 
patients living with multiple 
myeloma: an exploratory 
study. Psycho-Oncology 
20(2), 127-134.
Qualitative interview study (UK)
15 patients living with MM.
•	 Five themes around distress emerged: 1) Distress from 
experienced symptoms (dificulties with mobility caused 
considerable distress, but inancial rather than physical – long wait 
to receive DLA, often had to pay themselves for needed mobility 
equipment); 2) Distress from body image changes; 3) Distress 
caused by family and friends (Family and friends were overall 
praised for their support, but were also reported as causing distress. 
Noted that living with myeloma often represented a substantial 
inancial burden, especially for younger patients – several had 
to move back in with parents or families as could not afford 
mortgage/rent. Friends found to play a far greater role than is 
generally recognised, practically and inancially); 4) Distress from 
myeloma related info; 5) Distress from SCT.
9 Snowden, J. A., Ahmedzai, 
S. H., Ashcroft, J., D’Sa, 
S., Littlewood, T., Low, E., 
Lucraft, H., Maclean, R., 
Feyler, S., Pratt, G. and Bird, 
J (2011). Guidelines for 
supportive care in multiple 
myeloma 2011. British 
Journal of Haematology 
154(1), 76–103.
Best practice guidelines on supportive care in multiple myeloma
Produced by the British Committee for Standards in Haematology in 
conjunction with the UK Myeloma Forum (UKMF). Intended to be used 
in conjunction with Bird et al (2011) guidelines for management.
Recommendations for supportive care in myeloma cover following 
areas: pain management, peripheral neuropathy; skeletal 
complications; infection; anaemia; haemostasis and thrombosis; 
sedation; fatigue; nausea; vomiting; anorexia; constipation; 
diarrhoea; mucositis; bisphosphonate induced osteonecrosis of jaw; 
complementary therapies; holistic needs assessment; end of life care.
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1. As we suspected the term AAD was not well-used in the literature. High retrieval rather than high 
speciicity was our main concern; there is evidence that Google Scholar consistently achieves higher 
retrieval rates than other search engines (Cecchino, 2010).
2. 15–25% of newly diagnosed patients have mCRC at diagnosis and 25% of early stage CRC patients 
will develop metastases (Fu et al, 2011).
3. See NICE Guidance 131 (NICE, 2011) for current guidance for chemotherapy for advanced and 
metastatic CRC.
4. NICE Guidance (2011) states that all patients with primary CRC should be offered follow-up care and 
re- investigation should occur if there is any suspicion of recurrent disease. Follow-up investigations 
should cease if risks are greater than beneits and, or the patient can no longer tolerate treatment 
(NICE 2011). Other than medical tests (CT scans of chest, abdomen and pelvis, surveillance 
colonoscopy, and serum carcinoembryonic antigen tests [CEA]) NICE guidance recommends follow up 
should begin four to six weeks after initial treatment (NICE 2011).
5. We use the term ‘signiicant other’ here rather than carer, for two reasons. Firstly, not all those close to 
a patient with AAD may consider themselves – or be considered by services – to be a carer; secondly, 
we believe it is important to consider networks of support beyond a patient’s spouse/partner.
For more information please contact Recoverypackage@macmillan.org.uk
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